Search this site

Exec Summary: SoftBank has been investing in healthtech for several years, and there are signs that the company is about to make a big new play in the sector. In 2022, SoftBank Vision Fund 2 invested $1 billion in Alto Pharmacy, a digital pharmacy that delivers prescription drugs to patients. The company also invested $500 million in Ro Health, a telehealth company that provides primary care services to patients nationwide. These investments suggest that SoftBank is bullish on the future of healthtech. The company is likely to continue investing in this sector, and it is possible that SoftBank will make some major acquisitions and investments in the coming years. Here are some of the reasons why SoftBank is likely to make a big new play into healthtech: The healthcare industry is ripe for disruption. The healthcare industry is slow to adopt new technologies, but there is a growing demand for innovation. SoftBank is well-positioned to capitalize on this demand by investing in companies that are using technology to improve the delivery of healthcare. The healthtech market is growing rapidly. The global healthtech market is expected to grow from $350 billion in 2020 to $850 billion by 2025. This growth is being driven by a number of factors, including the aging population, the rise of chronic diseases, and the increasing use of technology in healthcare. SoftBank has a track record of success in healthtech. SoftBank has already invested in a number of successful healthtech companies, including Livongo Health and Omada Health. This track record of success gives SoftBank the credibility it needs to attract other investors to the healthtech sector. Engage with the HealthTech Community HealthTech M&A Newsletter from Nelson Advisors - Market Insights & Analysis for Founders & Investors. Subscribe today! https://lnkd.in/e5hTp_xb HealthTech M&A Advisory by Founders for Founders, Owners & Investors. Buy Side, Sell Side, Growth and Strategy mandates - Email lloyd@nelsonadvisors.co.uk HealthTech Thought Leadership from Nelson Advisors - Industry Insights & Analysis for Founders, Owners & Investors. Visit https://www.healthcare.digital Softbank's growing interest in AI and Generative AI Pitchbook recently quoted Softbank Chief Masayoshi Son as "ready to shift to 'offense mode' after being on the defensive" and that "after a period of refraining from making new investments the technology group is ready to make a big push into artificial intelligence." "Son said that the group didn't have spare cash three years ago, but after selling the majority of its shares in Alibaba, SoftBank has accumulated 5 trillion yen (about $35 billion)." "Additional capital could also soon come from an IPO of Arm, the UK chipmaker that SoftBank purchased in 2016 for $31 billion. Arm is in talks with Intel to anchor its upcoming IPO, and is reportedly preparing to debut in New York as early as September. Arm could raise $10 billion in the listing, Bloomberg reported." "While Son has long positioned SoftBank as a firm that seeks to capitalize on the AI revolution, the group didn't invest in any leading generative AI companies, including OpenAI." Source: https://pitchbook.com/news/articles/softbank-masayoshi-son-generative-ai-arm-chips Therefore one possibility is Softbank unveiling a number of both generative AI and AI investments in Healthtech in the next 12 months, for example: Virtual assistants: Virtual assistants like Apple's Siri and Amazon's Alexa can be used to answer medical questions, provide reminders for medications, and even book appointments. Machine learning: Machine learning algorithms can be used to analyze medical data to identify patterns and trends. This can help doctors to make better diagnoses and develop more effective treatments. Robotics: Robots are being used in surgery, rehabilitation, and other healthcare settings. Robots can perform tasks that are too difficult or dangerous for humans, and they can also provide companionship and support to patients. Virtual reality: Virtual reality is being used to train surgeons, provide pain relief, and even treat phobias. VR can create realistic simulations of medical procedures, which can help surgeons to practice their skills without putting patients at risk. Gene editing: Gene editing technologies like CRISPR are being used to develop new treatments for diseases. Gene editing can be used to correct genetic defects, and it can also be used to create new drugs and vaccines. Source: https://group.softbank/system/files/pdf/ir/presentations/2022/earnings-presentation_q4fy2022_01_en.pdf Softbank's strategy for healthcare SoftBank's strategy for healthcare is to invest in companies that are using technology to improve the delivery of healthcare. The company is focused on three key areas: Digital health: SoftBank invests in companies that are developing new digital tools for diagnosis, treatment, and patient engagement. This includes companies that are using artificial intelligence, machine learning, and other technologies to improve the way healthcare is delivered. Life sciences: SoftBank invests in companies that are developing new drugs, devices, and diagnostics. This includes companies that are using gene editing, stem cell therapy, and other cutting-edge technologies to develop new treatments for diseases. Healthcare infrastructure: SoftBank invests in companies that are developing new infrastructure for the healthcare industry. This includes companies that are developing new payment models, data analytics platforms, and other technologies that are transforming the way healthcare is delivered. SoftBank's investment strategy in healthcare is ambitious, but it has the potential to transform the way healthcare is delivered. The company is investing in companies that are using technology to address some of the biggest challenges in healthcare, such as chronic disease management, drug discovery, and patient engagement. Here are some of the healthtech companies SoftBank has invested in: Big Health: using digital therapeutics to expand access to non-drug alternatives for mental health. Forward: building an entirely new health care system by empowering doctors with technology and data to monitor and guide long-term health outcomes. Ping An Good Doctor: building a comprehensive, one-stop healthcare ecosystem platform. Omada Health: A digital health company that provides weight loss and chronic disease management programs to patients. Alto Pharmacy: A digital pharmacy that delivers prescription drugs to patients. Ro Health: A telehealth company that provides primary care services to patients nationwide. Proximie: empowering clinicians to virtually ‘scrub in’ to any operating room in the world. SoftBank's investment strategy in healthcare is likely to continue in the years to come. The company has the resources, the track record, and the vision to make a significant impact on this sector. Softbank Vision Fund 2 SoftBank Vision Fund 2 is a $100 billion venture capital fund that was launched in 2019. The fund is managed by SoftBank Group, a Japanese multinational conglomerate. The goal of SoftBank Vision Fund 2 is to invest in technology companies that are developing new technologies that have the potential to disrupt existing industries. The fund has invested in a wide range of companies, including: Arm Holdings: A British semiconductor company that develops chip designs for smartphones and other devices. ByteDance: A Chinese technology company that owns the popular social media app TikTok. Coupang: A South Korean e-commerce company that is often compared to Amazon. Didi Chuxing: A Chinese ride-hailing company that is the largest in the world. Ola: An Indian ride-hailing company that is the second largest in the world. SoftBank Vision Fund 2 has been criticized for its large investments in companies that have not yet turned a profit. However, the fund has also been praised for its willingness to invest in innovative companies that have the potential to change the world. Here are some of the key benefits of SoftBank Vision Fund 2: It can help to accelerate the growth of technology companies. By providing large sums of capital, SoftBank Vision Fund 2 can help to accelerate the growth of technology companies by giving them the resources they need to expand and develop new products and services. It can help to foster innovation. By investing in early-stage companies, SoftBank Vision Fund 2 can help to foster innovation by giving these companies the resources they need to develop new technologies and products. It can help to create jobs. By investing in technology companies, SoftBank Vision Fund 2 can help to create jobs by providing these companies with the resources they need to expand and hire new employees. Overall, SoftBank Vision Fund 2 has the potential to have a significant impact on the technology industry. The fund's large investments and focus on innovation can help to accelerate the growth of technology companies and create jobs. Future of Softbank AI investments Softbank is focused on a 3 layer AI investment strategy, from computational power to infrastructure to applications. The company is acquiring and investing in companies spanning the foundation layer, application layer and services layer. Foundation Layer: Computational Power Computational power is the ability of a computer system to process and execute instructions. It is measured in terms of FLOPS (floating-point operations per second). The higher the FLOPS, the faster the computer can process instructions. Computational power is important for a number of tasks, including: Scientific computing: Computational power is essential for scientific computing, which involves the use of computers to solve complex mathematical problems. Machine learning: Machine learning is a type of artificial intelligence that relies on computers to learn from data. Computational power is essential for machine learning, as it allows computers to process large datasets and identify patterns. Graphics processing: Computational power is also important for graphics processing, which involves the use of computers to generate and display images. Application Layer: SaaS and Infrastructure The application layer in AI refers to the use of AI technology to solve real-world problems. This can include tasks such as: Natural language processing: This is the ability of computers to understand and process human language. It is used in a variety of applications, such as chatbots, machine translation, and text analysis. Computer vision: This is the ability of computers to see and understand the world around them. It is used in a variety of applications, such as facial recognition, object detection, and self-driving cars. Machine learning: This is the ability of computers to learn from data. It is used in a variety of applications, such as fraud detection, predictive analytics, and personalized recommendations. The application layer in AI is constantly evolving, as new technologies are developed and new applications are found. As AI technology becomes more powerful, it is likely that the application layer will become even more widespread, with AI being used to solve a wider range of problems. Services Layer: User Applications The services layer is the layer in a multi-tiered application architecture that provides services to the user applications. It is responsible for providing the following services: Data access: The services layer provides access to the data that is stored in the data layer. This data can be accessed through a variety of mechanisms, such as SQL queries, REST APIs, and SOAP APIs. Business logic: The services layer implements the business logic of the application. This logic is responsible for processing the data and providing the functionality that the user applications need. Presentation logic: The services layer provides the presentation logic of the application. This logic is responsible for formatting the data and displaying it to the user. The services layer is a critical layer in a multi-tiered application architecture. It is responsible for providing the services that the user applications need to function. Here are some examples of user applications that use the services layer: Web applications: Web applications are applications that are accessed through a web browser. They use the services layer to access the data that is stored in the data layer and to process the data. Desktop applications: Desktop applications are applications that are installed on the user's computer. They use the services layer to access the data that is stored in the data layer and to process the data. Mobile applications: Mobile applications are applications that are installed on the user's mobile device. They use the services layer to access the data that is stored in the data layer and to process the data. The services layer is a critical layer in all multi-tiered application architectures. It is responsible for providing the services that the user applications need to function. Gearing up for a series of major new HealthTech investments Softbank has a history of investing in the healthcare industry, and it has been making a number of moves in recent months that suggest it is interested in making more investments in this area. For example, in January 2023, SoftBank announced that it was investing $700 million in Alto Pharmacy, a digital pharmacy that delivers prescription drugs to patients. This investment was the largest ever made in a digital pharmacy, and it signaled SoftBank's interest in the growing market for digital healthcare. In addition, SoftBank has been investing in a number of other healthcare companies, including Livongo Health, a diabetes management company, and Omada Health, a weight loss and chronic disease management company. These investments suggest that SoftBank is interested in investing in a variety of healthcare companies, from digital health startups to traditional healthcare companies. It is still too early to say for sure whether SoftBank will make a series of major new HealthTech investments. However, the company's recent moves suggest that it is likely to continue to invest in this area in the future. Here are some of the factors that suggest that SoftBank is gearing up for a series of major new HealthTech investments: The company's history of investing in the healthcare industry: SoftBank has a long history of investing in the healthcare industry. In the past, the company has invested in companies such as Livongo Health, Omada Health, and Guardant Health. This suggests that SoftBank has a strong track record of investing in healthcare companies and that it is likely to continue to invest in this area in the future. The growing market for digital healthcare: The market for digital healthcare is growing rapidly. This is due to a number of factors, such as the increasing adoption of smartphones and tablets, the growing demand for convenience, and the rising cost of healthcare. The growth of the digital healthcare market suggests that there are significant opportunities for investment in this area. SoftBank's recent moves in the healthcare industry: In recent months, SoftBank has made a number of moves that suggest it is interested in making more investments in the healthcare industry. For example, the company invested $700 million in Alto Pharmacy, a digital pharmacy that delivers prescription drugs to patients. This investment was the largest ever made in a digital pharmacy, and it signaled SoftBank's interest in the growing market for digital healthcare. Overall, the evidence suggests that SoftBank is gearing up for a series of major new HealthTech investments. The company has a history of investing in the healthcare industry, the market for digital healthcare is growing rapidly, and SoftBank has been making a number of moves in the healthcare industry in recent months. These factors suggest that SoftBank is likely to continue to invest in the healthcare industry in the future. Engage with the HealthTech Community HealthTech M&A Newsletter from Nelson Advisors - Market Insights & Analysis for Founders & Investors. Subscribe today! https://lnkd.in/e5hTp_xb HealthTech M&A Advisory by Founders for Founders, Owners & Investors. Buy Side, Sell Side, Growth and Strategy mandates - Email lloyd@nelsonadvisors.co.uk HealthTech Thought Leadership from Nelson Advisors - Industry Insights & Analysis for Founders, Owners & Investors. Visit https://www.healthcare.digital

HealthTech is having a major impact on the patient journey, from the moment a patient first seeks care to the point of discharge and beyond. Here are some of the ways that HealthTech is improving the patient journey: Providing access to information and education: HealthTech tools can give patients access to information about their condition, treatment options, and other resources. This can help patients to better understand their health and make informed decisions about their care. Providing patients with more information and control. HealthTech tools, such as patient portals and mobile apps, give patients access to their health information 24/7. This allows patients to track their health, communicate with their providers, and make informed decisions about their care. Making it easier to access care. Telehealth and virtual care make it possible for patients to see a doctor or other healthcare provider without having to leave their home. This is especially beneficial for patients who live in rural areas or who have difficulty traveling. Empowering patients to manage their own care: HealthTech tools can help patients to track their symptoms, manage their medications, and communicate with their healthcare providers. This can give patients a greater sense of control over their health and improve their overall health outcomes. Improving communication between patients and providers: HealthTech tools can make it easier for patients and providers to communicate with each other. This can help to improve the coordination of care and reduce the likelihood of errors. Streamlining the patient experience: HealthTech tools can streamline the patient experience by reducing the need for paperwork and making it easier to schedule appointments and access care. This can make the patient journey more efficient and convenient for patients. Personalizing care: HealthTech tools can be used to personalize care by gathering data about a patient's health and preferences. This information can be used to develop treatment plans that are tailored to the individual patient's needs. Improving the quality of care. HealthTech tools can help providers to diagnose and treat patients more accurately and efficiently. For example, AI-powered diagnostic tools can help providers to identify diseases earlier, and remote monitoring can help to prevent complications in patients with chronic conditions. Improving the patient experience. HealthTech tools can make the patient experience more convenient, comfortable, and personalized. For example, mobile apps can provide patients with reminders for appointments and medications, and virtual reality can be used to help patients with pain management and rehabilitation. Ramping up virtual care. Telehealth and other forms of virtual care are making it possible for patients to receive care from the comfort of their own homes. This can be especially beneficial for patients who live in rural areas or who have difficulty traveling. Using data to improve care. HealthTech tools can collect and analyze data about patients' health, which can be used to improve the quality of care. For example, data can be used to identify patients who are at risk for certain complications, or to track the effectiveness of new treatments. Overall, HealthTech is having a positive impact on the patient journey. By providing patients with access to information, empowering them to manage their own care, improving communication between patients and providers, and streamlining the patient experience, HealthTech is helping to make the healthcare system more efficient, effective, and patient-centered. Engage with the HealthTech Community HealthTech M&A Newsletter from Nelson Advisors - Market Insights & Analysis for Founders & Investors. Subscribe today! https://lnkd.in/e5hTp_xb HealthTech M&A Advisory by Founders for Founders, Owners & Investors. Buy Side, Sell Side, Growth and Strategy mandates - Email lloyd@nelsonadvisors.co.uk HealthTech Thought Leadership from Nelson Advisors - Industry Insights & Analysis for Founders, Owners & Investors. Visit https://www.healthcare.digital Here are some specific examples of how HealthTech is being used to improve the patient journey: Telehealth: Telehealth allows patients to connect with their healthcare providers remotely, using video conferencing or other technologies. This can make it easier for patients to access care, especially those who live in rural areas or have difficulty getting to the doctor's office. Wearable devices: Wearable devices, such as fitness trackers and smartwatches, can collect data about a patient's health, such as their heart rate, sleep patterns, and activity levels. This data can be used to track a patient's progress, identify potential health problems, and provide personalized feedback. Virtual reality: Virtual reality (VR) is being used to help patients with chronic pain, anxiety, and post-traumatic stress disorder (PTSD). VR can be used to create immersive environments that help patients to manage their symptoms and cope with stress. Artificial intelligence (AI): AI is being used to develop new diagnostic tools, personalize treatment plans, and improve the efficiency of healthcare delivery. For example, AI can be used to analyze large amounts of medical data to identify patterns that may be missed by human doctors. Patient portals allow patients to access their health records, schedule appointments, and communicate with their providers online. This can save patients time and hassle, and it can also help them to be more involved in their own care. Mobile apps can be used to track symptoms, manage medications, and connect with providers. This can help patients to stay on top of their health and to get the care they need when they need it. Telehealth allows patients to see a doctor or other healthcare provider from the comfort of their own home. This can be a convenient and affordable option for patients who live in rural areas or who have difficulty traveling. These are just a few examples of how HealthTech is being used to improve the patient journey. As HealthTech continues to evolve, we can expect to see even more innovative ways to use technology to make healthcare better for patients. HealthTech is making the patient journey more convenient, efficient, and informed. This is leading to better patient outcomes and a more satisfying experience for patients and providers alike. Here are some specific examples of how HealthTech is impacting the patient journey: A patient with diabetes can use a mobile app to track their blood sugar levels, receive medication reminders, and connect with a virtual care provider. A patient who is recovering from surgery can use a wearable device to monitor their heart rate and activity level. A pregnant woman can use an online portal to track her pregnancy and communicate with her doctor. A patient with cancer can use a virtual reality program to help them cope with the side effects of treatment. Software at numerous touchpoints of the patient journey Software has increased efficiency, capacity, and capability at numerous touchpoints of the patient journey. Here are some examples: Pre-appointment : Software can help patients to schedule appointments online, which can save time and hassle. It can also provide patients with information about their upcoming appointment, such as what to expect and what to bring. During the appointment : Software can help providers to collect and track patient data, which can improve the accuracy of diagnoses and the effectiveness of treatment. It can also help providers to communicate with each other more effectively, which can improve the coordination of care. Post-appointment : Software can help patients to manage their own care, such as tracking their symptoms and medications. It can also provide patients with access to educational resources, which can help them to better understand their condition and treatment plan. Overall, software is making the patient journey more efficient, convenient, and informed. This is leading to better patient outcomes and a more satisfying experience for patients and providers alike. Examples along the patient journey include: Pre-appointment: Online appointment scheduling can help patients to schedule appointments more quickly and easily. Patient portals can provide patients with access to their medical records, which can help them to prepare for appointments. Chatbots can answer patients' questions and provide them with basic information, which can free up providers' time. During the appointment: Electronic health records (EHRs) can help providers to collect and track patient data more efficiently. Clinical decision support (CDS) tools can help providers to make more informed decisions about treatment. Remote patient monitoring can allow providers to monitor patients' health remotely, which can reduce the need for in-person visits. Post-appointment: Patient portals can allow patients to view their test results and communicate with their providers. Telehealth can allow patients to receive care from the comfort of their own homes. Wearable devices can collect data about patients' health, which can be used to improve the effectiveness of treatment. These are just a few examples of how software is improving the patient journey. As software continues to evolve, we can expect to see even more ways that it can be used to improve the quality of care and the patient experience. Engage with the HealthTech Community HealthTech M&A Newsletter from Nelson Advisors - Market Insights & Analysis for Founders & Investors. Subscribe today! https://lnkd.in/e5hTp_xb HealthTech M&A Advisory by Founders for Founders, Owners & Investors. Buy Side, Sell Side, Growth and Strategy mandates - Email lloyd@nelsonadvisors.co.uk HealthTech Thought Leadership from Nelson Advisors - Industry Insights & Analysis for Founders, Owners & Investors. Visit https://www.healthcare.digital

Exec Summary: Patient messaging apps are a type of healthtech that allows patients to communicate with their healthcare providers (HCPs) in a secure and convenient way. These apps can be used to send messages, schedule appointments, and ask questions. There are a number of different business models for patient messaging apps. One common model is to charge HCPs a subscription fee for the use of the app. This model is attractive to HCPs because it allows them to provide a more convenient and efficient way for patients to communicate with them. Another common model is to charge patients a fee for using the app. This model is attractive to patients because it allows them to have a direct line of communication with their HCPs without having to go through the front desk. Some patient messaging apps also generate revenue through advertising. This model is less common, but it can be a viable option for apps that have a large user base. The best business model for a patient messaging app will depend on a number of factors, including the target market, the features of the app, and the competitive landscape. Here are some of the benefits of using a patient messaging app: Increased communication between patients and HCPs Improved patient satisfaction Reduced administrative costs Improved patient outcomes Here are some of the challenges of using a patient messaging app: Security and privacy concerns Lack of adoption by HCPs Lack of awareness among patients Overall, patient messaging apps have the potential to improve the efficiency and effectiveness of healthcare delivery. However, there are a number of challenges that need to be addressed before these apps can become widely adopted. Engage with the HealthTech Community HealthTech M&A Newsletter from Nelson Advisors - Market Insights & Analysis for Founders & Investors. Subscribe today! https://lnkd.in/e5hTp_xb HealthTech M&A Advisory by Founders for Founders, Owners & Investors. Buy Side, Sell Side, Growth and Strategy mandates - Email lloyd@nelsonadvisors.co.uk HealthTech Thought Leadership from Nelson Advisors - Industry Insights & Analysis for Founders, Owners & Investors. Visit https://www.healthcare.digital Patient messaging apps Patient messaging apps are mobile apps that allow patients to communicate with their healthcare providers in a secure and convenient way. These apps typically offer features such as secure messaging, appointment scheduling, medication reminders, and access to patient records. Patient messaging apps can improve communication between patients and their healthcare providers in a number of ways. For example, they can help patients to: Ask questions about their health Get advice from their doctor Schedule appointments Receive medication reminders Access their patient records Patient messaging apps can also help to improve the quality of care by: Reducing the number of missed appointments Improving patient satisfaction Facilitating better coordination of care Features and Benefits Patient messaging apps are a valuable tool for patients and healthcare providers. They can help to improve communication, coordination of care, and patient satisfaction. As the market for patient messaging apps continues to grow, we can expect to see even more innovative and user-friendly apps being developed. Here are some of the benefits of using patient messaging apps: Convenience: Patients can message their healthcare providers from anywhere, at any time. Security: Patient messaging apps use end-to-end encryption to protect patient data. Cost-effectiveness: Patient messaging apps can save patients and healthcare providers time and money. Improved communication: Patient messaging apps can help to improve communication between patients and their healthcare providers. Increased patient satisfaction: Patient messaging apps can help to increase patient satisfaction with their care. Business Models There are a few different business models that patient messaging apps can use. Subscription model In this model, patients pay a monthly or annual subscription fee to use the app. This is the most common business model for patient messaging apps, as it allows the app developers to generate a steady stream of revenue. Advertising model In this model, the app developers sell advertising space to businesses that want to reach their target audience. This can be a good way to generate revenue, but it can also be disruptive to the user experience if the ads are too intrusive. Freemium model In this model, the app is free to download and use, but there are some features that are only available to paying subscribers. This is a good way to attract a large number of users, and then encourage them to upgrade to a paid plan. Pay-per-use model In this model, patients only pay when they use certain features of the app. This can be a good way to generate revenue for features that are not used by all patients, such as video chat or secure messaging. The most successful patient messaging apps There are a few patient messaging apps that have reached the billion dollar valuation mark. These apps include: Amwell: Amwell is a telehealth company that allows patients to connect with doctors via video chat. The company has raised over $1 billion in funding and is valued at over $3 billion. Teladoc: Teladoc is another telehealth company that allows patients to connect with doctors via video chat. The company has raised over $2 billion in funding and is valued at over $13 billion. Doctor on Demand: Doctor on Demand is a telehealth company that allows patients to connect with doctors via video chat. The company has raised over $500 million in funding and is valued at over $1 billion. PatientsLikeMe: PatientsLikeMe is a social networking app for patients with chronic conditions. The app allows patients to connect with each other, share information, and track their progress. The company has raised over $100 million in funding and is valued at over $1 billion. These apps have all achieved success by providing patients with convenient and affordable access to healthcare. They have also helped to improve communication between patients and their doctors. As the patient messaging app market continues to grow, we can expect to see even more apps reaching the billion dollar valuation mark. Here are some other patient messaging apps that are worth mentioning: MyChart: MyChart is a patient portal that allows patients to access their medical records, schedule appointments, and communicate with their doctors. The app is owned by the Cleveland Clinic and is used by over 25 million patients. Oscar: Oscar is a health insurance company that offers a mobile app that allows patients to track their health, communicate with their doctors, and find doctors. The app is used by over 1 million patients. Livongo: Livongo is a healthtech company that offers a mobile app that helps patients with chronic conditions manage their health. The app provides patients with personalized coaching, medication reminders, and access to a network of doctors. The company is valued at over $1 billion. These apps are all providing valuable services to patients and are helping to improve the quality of care. As the patient messaging app market continues to grow, we can expect to see even more apps being developed that can help patients improve their health. Conclusion: The patient messaging app market is growing rapidly, and there are a number of new apps being launched all the time. As the market continues to evolve, we can expect to see new and innovative business models emerge. Key factors to consider when choosing a business model for a patient messaging app: The target market: The target market for a patient messaging app will affect the best business model. For example, an app that is targeted at patients with chronic conditions may be more successful with an advertising-based model, while an app that is targeted at healthcare providers may be more successful with a subscription-based model. The features offered: The features offered by the app will also affect the best business model. For example, an app that offers a wide range of features, such as appointment scheduling, medication reminders, and secure messaging with doctors, may be more successful with a subscription-based model, while an app that offers more basic features may be more successful with a pay-per-use model. The competition: The competition in the market will also affect the best business model. For example, if there are a number of other apps that offer similar features, a subscription-based model may be more successful, as it will allow the app developer to differentiate their app from the competition. The most successful business models for patient messaging apps include: Subscription fees: Patients pay a monthly or annual fee to use the app. This model is often used by apps that offer a wide range of features, such as appointment scheduling, medication reminders, and secure messaging with doctors. Pay-per-use: Patients pay a fee for each use of the app, such as for sending a message to their doctor or scheduling an appointment. This model is often used by apps that offer more basic features. Advertising: The app displays ads to patients, and the app developer earns revenue from the ads. This model is typically used by apps that have a large user base and can attract a significant amount of ad traffic. Selling data: The app collects data about patients, such as their health information and their usage of the app. The app developer then sells this data to healthcare providers or pharmaceutical companies. Engage with the HealthTech Community HealthTech M&A Newsletter from Nelson Advisors - Market Insights & Analysis for Founders & Investors. Subscribe today! https://lnkd.in/e5hTp_xb HealthTech M&A Advisory by Founders for Founders, Owners & Investors. Buy Side, Sell Side, Growth and Strategy mandates - Email lloyd@nelsonadvisors.co.uk HealthTech Thought Leadership from Nelson Advisors - Industry Insights & Analysis for Founders, Owners & Investors. Visit https://www.healthcare.digital

Exec Summary: Allurion, a weight loss company that makes a swallowable gastric balloon, went public this week on August 2, 2023 through a merger with a special purpose acquisition company (SPAC) called Compute Health. The deal valued Allurion at $500 million. Compute Health is a blank-check company that was formed to acquire a health care technology business. The company is led by former Medtronic CEO Omar Ishrak. The SPAC merger was announced in February 2023. The deal included $100 million in cash from the SPAC and a private investment in public equity (PIPE) of $50 million. The PIPE was led by RTW Investments. Allurion's gastric balloon is a non-surgical weight loss device that is inserted into the stomach through the mouth. The balloon is filled with saline and stays in the stomach for up to 12 weeks. During that time, the balloon helps to reduce the amount of food that the person can eat. Allurion's gastric balloon is FDA-approved and has been shown to be effective in helping people lose weight. The company's clinical trials have shown that people who use the balloon lose an average of 20% of their body weight. The SPAC merger gives Allurion access to capital that it can use to expand its sales and marketing efforts. The company also plans to use the money to develop new products and services. Allurion's IPO is the first health tech IPO of 2023. The company's success will be seen as a sign of whether the health tech IPO market is thawing after a period of dormancy. Here are some of the key takeaways from Allurion's IPO: The company's gastric balloon is a non-surgical weight loss device that is FDA-approved. The SPAC merger gave Allurion access to capital that it can use to expand its sales and marketing efforts. The company plans to use the money to develop new products and services. Allurion's IPO is the first health tech IPO of 2023 Allurion is facing some challenges, however. The obesity market is highly competitive and there are a number of other weight loss products on the market. Additionally, the company has been criticized for its high price tag. The Obalon Balloon System costs $2,000 and the digital weight loss program costs $199 per month. Despite these challenges, Allurion is well-positioned for growth. The obesity market is a large and growing market, and Allurion's products have the potential to help millions of people lose weight. The company is also expanding its product offerings and it is developing new technologies to address the obesity epidemic. It will be interesting to see how Allurion performs as a public company. The company has a strong management team and a promising product portfolio. However, the company will need to overcome the challenges of the obesity market and the high price of its products in order to be successful. Engage with the HealthTech Community HealthTech M&A Newsletter from Nelson Advisors - Market Insights & Analysis for Founders & Investors. Subscribe today! https://lnkd.in/e5hTp_xb HealthTech M&A Advisory by Founders for Founders, Owners & Investors. Buy Side, Sell Side, Growth and Strategy mandates - Email lloyd@nelsonadvisors.co.uk HealthTech Thought Leadership from Nelson Advisors - Industry Insights & Analysis for Founders, Owners & Investors. Visit https://www.healthcare.digital Intro to Allurion Allurion is a medical technology company that develops and markets weight loss products. The company's flagship product is the Allurion Gastric Balloon, a swallowable, procedure-free balloon that is inserted into the stomach through the mouth. The balloon is filled with saline and stays in place for up to 12 weeks. During this time, the balloon helps to reduce the amount of food that the person can eat, leading to weight loss. Allurion was founded in 2010 and is headquartered in Boston, Massachusetts. The company has received FDA approval for the Allurion Gastric Balloon in the United States, Europe, and other countries. In addition to the Allurion Gastric Balloon, Allurion is also developing other weight loss products, including a digital weight loss program and a non-surgical weight loss pill. The company's mission is to "end obesity globally, helping our patients to live fuller, longer lives." Here are some of the benefits of using Allurion's weight loss products: Non-surgical: The Allurion Gastric Balloon is a non-surgical device, which means that there is no need for anesthesia or incisions. Procedure-free: The Allurion Gastric Balloon is inserted into the stomach through the mouth, so there is no need for surgery. Effective: The Allurion Gastric Balloon has been shown to help people lose an average of 10% of their body weight. Safe: The Allurion Gastric Balloon is a safe and effective weight loss device. Allurion's Investors Allurion has raised over $150 million in funding from a number of venture capital firms, including: Romulus Capital Novalis LifeSciences Venrock GV (formerly Google Ventures) NEA (New Enterprise Associates) Northpond Partners Tau Ventures Runway Growth Capital These investors are attracted to Allurion's innovative technology and its potential to disrupt the weight loss market. The company's gastric balloon is a non-surgical, minimally invasive procedure that is safe and effective for many people. Allurion's venture capital investors believe that the company has the potential to become a major player in the weight loss market. In addition to venture capital funding, Allurion has also received funding from the National Institutes of Health (NIH). The NIH grant is supporting the company's research on the use of its gastric balloon for the treatment of obesity. Allurion's venture capital investors and the NIH grant are a testament to the company's potential to make a significant impact on the weight loss market. With continued investment and development, Allurion could become a leading provider of weight loss solutions. Source: https://www.sec.gov/Archives/edgar/data/1828608/000121390023009565/ea172635ex99-2_compute.htm Intro to Compute Health Compute Health Acquisition Corp. (NYSE: CPUH.U, CPUH & CPUH WS) is a special purpose acquisition company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganisation or similar business combination with one or more businesses. On February 9, 2021, Compute Health closed its initial public offering of $862.5 million. The company is led by the management team of Omar Ishrak, Jean Nehmé and Joshua Fink. The company’s strategy is to focus on healthcare businesses that are already leveraging or have the potential to leverage computational power, with an emphasis on companies in the medical device space, including imaging and robotics. https://www.compute-health.com Compute Health Allurion strategy The Compute Health Allurion strategy is to combine Allurion's innovative weight loss technology with Compute Health's expertise in healthcare technology to create a leading provider of weight loss solutions. The company plans to use the funds from the merger to expand Allurion's sales and marketing efforts, develop new products, and pursue international growth. Compute Health believes that the combination of Allurion's technology and its own expertise will allow the company to disrupt the weight loss market. The company's goal is to become the leading provider of weight loss solutions by 2025. Here are some of the key elements of the Compute Health Allurion strategy: Expand sales and marketing: Compute Health plans to expand Allurion's sales and marketing efforts to reach more patients and providers. The company plans to do this by increasing its presence at medical conferences, launching a new marketing campaign, and expanding its sales team. Develop new products: Compute Health plans to develop new products that build on Allurion's technology. The company is currently working on a new gastric balloon that is smaller and easier to swallow. The company is also developing a digital platform that will help patients track their weight loss progress. Pursue international growth: Compute Health plans to pursue international growth by expanding Allurion's presence in new markets. The company is currently focused on expanding in Europe and Asia. The Compute Health Allurion strategy is ambitious, but the company has the potential to be successful. The company has a strong management team with a proven track record in the healthcare industry. The company also has a unique technology that has the potential to disrupt the weight loss market. If Compute Health is able to execute on its plans, it could become a leading provider of weight loss solutions in the years to come. Compute Health Allurion: key risks The Compute Health Allurion merger has a number of key risks, including: The weight loss market is competitive. There are a number of other companies that are developing innovative weight loss technologies. Compute Health and Allurion will need to compete with these companies to attract patients and grow their market share. The Allurion gastric balloon is a new technology. There is no long-term safety data on the Allurion gastric balloon. It is possible that the balloon could have side effects that are not yet known. The Allurion weight loss program is expensive. The Allurion weight loss program is more expensive than other weight loss programs. This could make it difficult for the company to attract patients. The company is a SPAC. SPACs are a type of blank-check company that is formed to acquire a business. There is no guarantee that Compute Health will be able to complete a successful acquisition. Overall, the Compute Health Allurion merger is a high-risk, high-reward investment. The company has a strong team with a proven track record, and it has the resources to execute on its plans. However, the company faces a number of challenges, including the competitive weight loss market and the lack of long-term safety data on the Allurion gastric balloon. Here are some additional risks that could impact the Compute Health Allurion merger: Changes in the regulatory environment. The regulatory environment for weight loss technologies is constantly changing. If there are changes in the regulations, it could impact the company's ability to market and sell its products. Economic downturn. A economic downturn could lead to a decrease in demand for weight loss products. This could impact the company's revenue and profitability. New technologies. The development of new weight loss technologies could make the Allurion gastric balloon less competitive. The company will need to continue to innovate in order to stay ahead of the competition. Compute Health Allurion: future predictions It is difficult to make predictions about the future of Compute Health Allurion. The company is still in its early stages, and it faces a number of challenges. However, the company has a strong team with a proven track record, and it has the resources to execute on its plans. If the company is successful, it could become a major player in the weight loss market. The global weight loss market is worth over $200 billion, and there is a growing demand for effective and convenient weight loss solutions. Here are some predictions for the future of Compute Health Allurion: The company will expand its sales and marketing efforts. This will help the company reach more patients and grow its market share. The company will develop new products. This will help the company offer a wider range of weight loss solutions and stay ahead of the competition. The company will pursue international growth. This will help the company reach more patients and grow its revenue. The company's success will depend on a number of factors, including the regulatory environment, the economic climate, and the development of new technologies. However, if the company is able to overcome these challenges, it could become a major player in the weight loss market. Here are some additional predictions for the future of Compute Health Allurion: The company's stock price will fluctuate. The stock price will be volatile as the company navigates the challenges of the weight loss market. The company will face competition from other weight loss companies. The company will need to continue to innovate in order to stay ahead of the competition. The company's products will be subject to regulatory scrutiny. The company's products will need to meet regulatory requirements in order to be marketed and sold. Engage with the HealthTech Community HealthTech M&A Newsletter from Nelson Advisors - Market Insights & Analysis for Founders & Investors. Subscribe today! https://lnkd.in/e5hTp_xb HealthTech M&A Advisory by Founders for Founders, Owners & Investors. Buy Side, Sell Side, Growth and Strategy mandates - Email lloyd@nelsonadvisors.co.uk HealthTech Thought Leadership from Nelson Advisors - Industry Insights & Analysis for Founders, Owners & Investors. Visit https://www.healthcare.digital

Exec Summary: Babylon/MindMaze merger proposed by AlbaCore Capital LLP has been called off, will no longer proceed as previously announced. Babylon is in discussions with a number of new parties looking at new strategic alternatives for its businesses in both the UK and US. Babylon is pursuing the divestiture of its UK business to third parties that may provide financing to assure the continuity of the operations. Press release stated ... "Babylon Holdings Limited (OTC Pink: BBLNF) (“Babylon”, and together with its subsidiaries, the “Group”) today announced that the transaction proposed by AlbaCore Capital LLP (“AlbaCore”) and MindMaze Group SA (“MindMaze”), for a business combination of Babylon’s core operating subsidiaries with MindMaze, previously announced on June 23, 2023 (the “Previously Proposed Transaction”), will not proceed. Following Babylon’s receipt of funding under its amended bridge notes facility with AlbaCore, Babylon has no binding commitment for additional financing to continue its business operations. As a result, the Group is exploring new strategic alternatives in order to find the best possible outcome for its UK business. Babylon remains focused on continuing the day to day operations of its UK business, providing accessibility of its healthcare services and the highest standards of care for its patients and members. The Group is pursuing the divestiture of its UK business to third parties that may provide financing to assure the continuity of the operations. Babylon has built a successful, distinct and sustainable UK business which provides high quality healthcare to many. However, it cannot provide assurance that any of these initiatives will result in Babylon entering into a definitive agreement for or completing a divestiture. Further, Babylon is exiting its core US business and plans to safely transition its US members to other providers, and continues to pursue its previously disclosed process for the sale of the Meritage Medical Network independent physicians association business (the “IPA Business”, and the sale of the IPA Business, the UK business or another particular business of Babylon is referred to as a “Third Party Sale”). In order to explore these opportunities for a Third Party Sale and enable business continuity, Babylon is in discussions with potential strategic partners to secure additional funding. Babylon cannot provide assurance that it will be able to secure sufficient liquidity to fund the operations of the Group’s businesses. To the extent that Babylon is unable to secure additional financing and complete a Third Party Sale of a particular business, the applicable entities of the Group will file for bankruptcy protection or implement other alternatives for an orderly wind down and liquidation or dissolution, which may include commencing Chapter 7 proceedings under the U.S. Bankruptcy Code and/or a UK administration for the applicable entities of the Group in the near term. Any Third Party Sale will be subject to AlbaCore’s rights under its debt agreements with Babylon, and the aggregate proceeds of any Third Party Sales are not expected to exceed the total amount of the Group’s indebtedness to AlbaCore. As a result, any such transaction will not provide for any payment to Babylon’s Class A ordinary shareholders and other equity instrument holders." Source: https://www.businesswire.com/news/home/20230806277244/en/Babylon-In-Discussions-of-New-Strategic-Alternatives-for-its-Businesses Merger Announcement on June 23rd 2023 Babylon Holdings Limited (NYSE: BBLN) has agreed to the recapitalisation and take private proposal from AlbaCore Capital LLP which will result in a merger with Swiss based MindMaze Group SA. In combination with MindMaze, a global leader in brain technology and digital neurotherapeutic solutions for brain health and recovery, the new entity is positioned to uniquely address patient and member needs across the continuum-of-care, from healthcare through sick care. Babylon and MindMaze believe that the combined entity will form a powerful digital-first global AI-driven healthcare business that will help transform the industry from sick care to predictive and preventative healthcare. Babylon and MindMaze will be dedicated to improving patient engagement and access to high quality optimized healthcare by tackling a broad range of chronic conditions, including but not limited to neurological conditions. Babylon and its management will continue to operate and deliver on its existing business plan. Over the mid-to-long term Babylon and MindMaze intend to align the strengths of their organisations to deliver a truly novel care paradigm and deliver exceptional outcomes for all stakeholders. The transaction is expected to close in July 2023 and will not provide for any payment to Babylon Holdings Limited’s Class A ordinary shareholders or other equity instrument holders, as AlbaCore will be exercising rights under its debt agreements with Babylon, and the go-forward private business will be transferred to private ownership. Therefore, the transaction would transfer core operating subsidiaries of Babylon to MindMaze, and Babylon Holdings Limited’s Class A ordinary shares will cease trading on the NYSE under the ticker symbol ‘BBLN’. Sources: https://www.businesswire.com/news/home/20230623670219/en/Babylon-Announces-Update-on-Take-Private-Proposal Engage with the HealthTech Community HealthTech M&A Newsletter from Nelson Advisors - Market Insights & Analysis for Founders & Investors. Subscribe today! https://lnkd.in/e5hTp_xb HealthTech M&A Advisory by Founders for Founders, Owners & Investors. Buy Side, Sell Side, Growth and Strategy mandates - Email lloyd@nelsonadvisors.co.uk HealthTech Thought Leadership from Nelson Advisors - Industry Insights & Analysis for Founders, Owners & Investors. Visit https://www.healthcare.digital AlbaCore Capital Group AlbaCore Capital Group is a European investment firm and bespoke solutions provider, focusing on private debt and opportunistic credit investments. The firm was founded in 2016 by David Allen, Bill Ammons, and Deborah Cohen Malka, who previously worked together in the Canada Pension Plan Investment Board's Principal Credit Investments business in London. AlbaCore's core investment team has over 30 years of experience in the credit markets, and the firm has a track record of investing in and managing a wide range of credit strategies, including direct lending, collateralized loan obligations (CLOs), and distressed debt. The firm has offices in London, Dublin, and New York, and manages over $19 billion in assets. AlbaCore's clients include institutional investors, family offices, and high-net-worth individuals. The firm's investment philosophy is to focus on the long term and to build relationships with its portfolio companies. AlbaCore seeks to invest in companies that have strong management teams, sustainable business models, and the potential for growth. The firm's recent investments include Babylon Health, MindMaze, and Just Eat Takeaway.com. AlbaCore has also been active in the CLO market, and has priced five CLOs since 2017. AlbaCore is a leading alternative investment manager in Europe, and its track record and investment philosophy have attracted a strong following from institutional investors. The firm is well-positioned to continue to grow in the years to come. Here are some of the key facts about AlbaCore Capital Group: Founded in 2016 Headquarters in London Offices in Dublin and New York Over $19 billion in assets under management Investment focus: private debt and opportunistic credit Investment philosophy: long-term oriented, relationship-driven Recent investments: Babylon Health, MindMaze, Just Eat Takeaway.com Track record: consistently outperformed the market in the long term MindMaze MindMaze is a global leader in the development of AI-driven digital neurotherapeutics. The company's mission is to "empower people to recover and improve their brain function through innovative technologies." MindMaze's technology platform combines virtual reality, brain-computer interfaces, and artificial intelligence to create personalised, immersive, and engaging experiences that help patients recover from neurological injuries and diseases. The company's products are used by patients, clinicians, and researchers in over 100 countries around the world. Some of MindMaze's most notable products include: Muse: A brain-computer interface headband that helps users improve their focus, attention, and relaxation. Infinity: A virtual reality platform that helps patients with stroke, Parkinson's disease, and other neurological conditions regain motor function. Izar: A smart peripheral that helps patients with hand dexterity impairment improve their hand function. MindMaze's technology has been shown to be effective in a number of clinical trials. For example, a study published in the journal Neurology found that patients with stroke who used MindMaze's Infinity platform for 6 weeks showed significant improvements in their motor function. MindMaze is a privately held company headquartered in Lausanne, Switzerland. The company was founded in 2012 by Tej Thakur, Jaggi Sidhu, and Dr. Gerwin Schalk. MindMaze has raised over $100 million in funding from investors such as SoftBank Vision Fund, Fidelity Investments, and Robert Bosch Venture Capital. MindMaze is a rapidly growing company with a bright future. The company's technology has the potential to revolutionize the way we treat neurological injuries and diseases. With continued investment and development, MindMaze could become one of the leading players in the digital health industry. Here are some of the key benefits of MindMaze's AI-driven digital neurotherapeutics: Personalized: The company's technology is personalized to each individual patient, based on their specific needs and goals. Immersive: The company's products use virtual reality and other immersive technologies to create a more engaging and effective therapy experience. Engaging: The company's products are designed to be engaging and motivating, which helps patients stay motivated to continue with their therapy. Effective: The company's technology has been shown to be effective in a number of clinical trials. Background to the merger: VR, clinical trials and stroke patients Babylon Health and MindMaze are two leading companies in the digital health space. Babylon Health is a telemedicine company that provides users with access to healthcare professionals through a mobile app. MindMaze is a company that develops AI-driven digital neurotherapeutics. The two companies have partnered to develop a new product called Babylon MindMaze. This product combines Babylon Health's telemedicine platform with MindMaze's AI-driven neurotherapeutics to provide patients with a more personalized and effective way to manage neurological conditions. Babylon MindMaze is currently being used in a clinical trial in the United Kingdom. The trial is evaluating the effectiveness of the product in treating patients with stroke. The results of the trial are expected to be released in 2023. If the trial is successful, Babylon MindMaze could have a significant impact on the way we treat neurological conditions. The product could help patients recover more quickly and effectively from stroke and other neurological injuries and diseases. Here are some of the key benefits of the Babylon MindMaze partnership: Personalized: The product is personalized to each individual patient, based on their specific needs and goals. Immersive: The product uses virtual reality and other immersive technologies to create a more engaging and effective therapy experience. Engaging: The product is designed to be engaging and motivating, which helps patients stay motivated to continue with their therapy. Effective: The product is based on MindMaze's AI-driven neurotherapeutics, which have been shown to be effective in clinical trials. Looking to the future, the next chapter for Babylon The future of Babylon Health and MindMaze clinical trials is bright. The two companies are working on a number of promising projects that have the potential to revolutionize the way we treat neurological conditions. One of the most exciting projects is the development of a digital rehabilitation platform for patients with stroke. The platform combines Babylon Health's clinical expertise with MindMaze's AI-driven technology to create a personalized and immersive rehabilitation experience. The platform is still in development, but it has the potential to revolutionize the way stroke patients are treated. By combining clinical expertise with AI-driven technology, the platform can provide patients with a more effective and engaging rehabilitation experience. Another promising project is the development of a digital platform for patients with Parkinson's disease. This platform will use MindMaze's AI-driven technology to help patients improve their motor function. The Babylon Health and MindMaze clinical trials are still in the early stages, but they have the potential to make a significant impact on the lives of patients with neurological conditions. The two companies are working hard to develop these platforms and bring them to market. Here are some of the key factors that could influence the future of Babylon Health and MindMaze clinical trials: The success of the current clinical trials. If the trials are successful, it will provide strong evidence that the platforms are effective and safe. This will make it more likely that the platforms will be approved for use by regulatory agencies. The development of new AI-driven technologies. As AI-driven technologies continue to develop, they could be used to improve the effectiveness and efficiency of the platforms. This could make the platforms more attractive to patients and healthcare providers. The growth of the digital health market. The digital health market is growing rapidly, and this could create a larger market for the platforms. This could make it more feasible for Babylon Health and MindMaze to develop and market the platforms. Engage with the HealthTech Community HealthTech M&A Newsletter from Nelson Advisors - Market Insights & Analysis for Founders & Investors. Subscribe today! https://lnkd.in/e5hTp_xb HealthTech M&A Advisory by Founders for Founders, Owners & Investors. Buy Side, Sell Side, Growth and Strategy mandates - Email lloyd@nelsonadvisors.co.uk HealthTech Thought Leadership from Nelson Advisors - Industry Insights & Analysis for Founders, Owners & Investors. Visit https://www.healthcare.digital

Exec Summary: The proposed merger between UnitedHealth Group and EMIS has raised concerns from the Competition and Markets Authority (CMA) about the impact it could have on competition in the market for population health management services in the UK. Population health management is the use of data and analytics to improve the health of a population, rather than just treating individual patients. It can involve things like identifying people who are at risk of developing chronic diseases, providing them with preventive care, and monitoring their progress. EMIS is a leading supplier of population health management services to the NHS. Its products include EMIS Web, which is an electronic patient record system used by GPs, and EMIS Insight, which is a data analytics platform. UnitedHealth is a large healthcare company that also provides population health management services. The CMA is concerned that the merger could lead to UnitedHealth becoming too dominant in the market for population health management services. This could lead to higher prices for NHS patients and reduced innovation in the sector. In March 2023, the CMA provisionally found that the merger could substantially reduce competition in the market for population health management services. The CMA is now considering whether to refer the merger to a phase 2 investigation. If the merger is referred to a phase 2 investigation, UnitedHealth and EMIS will have the opportunity to offer undertakings to address the CMA's concerns. These undertakings could include selling off part of their business or agreeing to certain restrictions on their activities. The CMA's decision on the UnitedHealth-EMIS merger is expected to be made in August 2023. Here are some of the potential impacts of the merger on the NHS: Higher prices for NHS patients: UnitedHealth could use its market power to raise prices for its population health management services. This would increase the cost of care for NHS patients. Reduced innovation: The merger could lead to reduced innovation in the population health management sector. UnitedHealth may be less likely to invest in new technologies and services if it does not face competition from other providers. Reduced choice for NHS patients: The merger could reduce choice for NHS patients. If UnitedHealth becomes the dominant provider of population health management services, patients may have fewer options to choose from. The CMA is carefully considering the potential impacts of the merger on the NHS before making a final decision. The timetable for the UnitedHealth Group EMIS merger is as follows: January 20, 2023: The Competition and Markets Authority (CMA) in the UK launches a Phase 1 investigation into the merger. January 20 to February 3, 2023: The CMA invites third parties to comment on the merger. March 17, 2023: The CMA announces that it has completed its Phase 1 investigation and is referring the merger for an in-depth Phase 2 investigation. April 27, 2023: The CMA publishes a Notice of Extension, extending the deadline for its Phase 2 investigation by 40 working days. May 17, 2023: The CMA publishes its Phase 2 decision, finding that the merger is likely to substantially lessen competition in the market for population health management services in the UK. August 12, 2023: The CMA's deadline for making a final decision on the merger. If the CMA does not approve the merger, UnitedHealth and EMIS would need to offer undertakings to address the competition concerns. These undertakings could include selling off part of their PHM businesses or agreeing to certain pricing and access terms. The CMA's decision on the UnitedHealth-EMIS merger is expected to be made in August 2023. Engage with the HealthTech Community HealthTech M&A Newsletter from Nelson Advisors - Market Insights & Analysis for Founders & Investors. Subscribe today! https://lnkd.in/e5hTp_xb HealthTech M&A Advisory by Founders for Founders, Owners & Investors. Buy Side, Sell Side, Growth and Strategy mandates - Email lloyd@nelsonadvisors.co.uk HealthTech Thought Leadership from Nelson Advisors - Industry Insights & Analysis for Founders, Owners & Investors. Visit https://www.healthcare.digital Background to the UnitedHealth Group EMIS merger: In January 2023, UnitedHealth Group announced that it would acquire EMIS Group Plc for £1.2 billion. EMIS Group is a UK-based healthcare software company that provides a range of products and services to healthcare providers, including electronic health records (EHRs), patient management systems, and clinical decision support tools. UnitedHealth Group is a US-based healthcare company that provides a range of healthcare-related products and services, including health insurance, healthcare management, and health data analytics. The merger was met with opposition from some patient groups and healthcare providers, who argued that it would reduce competition and lead to higher prices. The Competition and Markets Authority (CMA) in the UK is currently investigating the merger to determine if it will reduce competition in the market for healthcare IT services. The CMA has until July 12, 2023 to make a decision on whether or not to approve the merger. Here are some of the key issues that the CMA is likely to consider when making its decision: The impact of the merger on competition: The CMA will consider whether the merger will reduce competition in the market for healthcare IT services. If the CMA believes that the merger will reduce competition, it is likely to block the merger. The impact of the merger on consumers: The CMA will also consider the impact of the merger on consumers. If the CMA believes that the merger will lead to higher prices or lower quality of service for consumers, it is likely to block the merger. The views of third parties: The CMA will also consider the views of third parties, such as patient groups, healthcare providers, and other businesses in the healthcare IT sector. If the CMA receives a lot of negative feedback from third parties, it is more likely to block the merger. Arguments for and against the UnitedHealth Group EMIS merger: Arguments in favour of the merger: The merger would create a more comprehensive healthcare IT platform: UnitedHealth Group and EMIS are both major providers of healthcare IT solutions. The merger would combine their strengths and create a more comprehensive platform that could better serve the needs of healthcare providers and patients. The merger would allow UnitedHealth Group to expand its reach into the UK market: UnitedHealth Group is a major player in the US healthcare market. The merger would allow it to expand its reach into the UK market, which is a growing market for healthcare IT solutions. The merger would create jobs: The merger would create jobs in the UK. UnitedHealth Group has said that it plans to invest £1 billion in the UK over the next five years. This investment would help to create jobs in the healthcare IT sector and other sectors of the economy. Arguments against the merger: The merger would reduce competition: UnitedHealth Group is a large player in the healthcare industry. The merger would give it a larger market share in the healthcare IT sector. This could lead to higher prices and lower quality of service for consumers. The merger would give UnitedHealth Group too much power: UnitedHealth Group is already a large and powerful company. The merger would give it even more power. This could lead to concerns about patient privacy and data security. The merger would not be in the best interests of patients: The merger would be driven by profit, not by the needs of patients. This could lead to higher prices, lower quality of care, and less choice for patients. Overall, there are both pros and cons to the UnitedHealth Group EMIS merger. The CMA will need to weigh these factors carefully before making a decision on whether or not to approve the merger. 3 key factors in the CMA's decision on the UnitedHealth Group EMIS merger The impact of the merger on competition: The CMA will consider whether the merger will reduce competition in the market for healthcare IT services. This will depend on a number of factors, including the size and market share of the merging companies, the number of other competitors in the market, and the barriers to entry for new businesses. The impact of the merger on consumers: The CMA will also consider the impact of the merger on consumers. This will depend on a number of factors, including the prices of healthcare IT services, the quality of service, and the choice of providers available to consumers. The views of third parties: The CMA will also consider the views of third parties, such as patient groups, healthcare providers, and other businesses in the healthcare IT sector. These parties may provide evidence to the CMA about the potential impact of the merger on competition and consumers. Overall, the CMA's decision on the UnitedHealth Group EMIS merger will depend on a number of factors, including the impact of the merger on competition and consumers. Engage with the HealthTech Community HealthTech M&A Newsletter from Nelson Advisors - Market Insights & Analysis for Founders & Investors. Subscribe today! https://lnkd.in/e5hTp_xb HealthTech M&A Advisory by Founders for Founders, Owners & Investors. Buy Side, Sell Side, Growth and Strategy mandates - Email lloyd@nelsonadvisors.co.uk HealthTech Thought Leadership from Nelson Advisors - Industry Insights & Analysis for Founders, Owners & Investors. Visit https://www.healthcare.digital

Exec Summary: The five funding trends for Telehealth in the last 12 months are 1) Gastrointestinal care 2) Mental health 3) Weight management 4) Women's health 5) Wound care. The telehealth industry has seen a significant increase in funding in recent years, with the global market size expected to reach $634.7 billion by 2027. This growth is being driven by a number of factors, including the COVID-19 pandemic, which accelerated the adoption of telehealth services, and the increasing demand for convenient and affordable healthcare options. Here are some of the recent funding trends in the telehealth industry: Increased funding for startups: In 2022, venture capitalists invested a record $27.5 billion in telehealth startups, up from $16.8 billion in 2021. This trend is expected to continue in 2023, as investors look to capitalize on the growth of the telehealth market. Focus on specific areas: Investors are increasingly focusing on specific areas of telehealth, such as mental health, chronic care management, and women's health. This is because these areas have a large and growing patient population that is underserved by traditional healthcare providers. Development of new technologies: Telehealth providers are developing new technologies to improve the quality and efficiency of care. These technologies include virtual reality, artificial intelligence, and remote patient monitoring. Collaboration between healthcare providers and technology companies: Healthcare providers and technology companies are increasingly collaborating to develop and deliver telehealth services. This collaboration is helping to bring telehealth to more patients and improve the quality of care. The telehealth industry is still in its early stages of development, but it is growing rapidly. The recent funding trends suggest that the industry is poised for continued growth in the years to come. Here are some specific examples of recent funding rounds in the telehealth industry: In April 2023, Avi Medical, a German telehealth startup, raised €50 million in Series B funding. In May 2023, Ginger, a US-based mental health telehealth company, raised $100 million in Series D funding. In June 2023, Medoc, a Brazilian telehealth company, raised $50 million in Series C funding. In August 2023, Women's Telehealth, a US-based women's health telehealth company, raised $30 million in Series A funding. These funding rounds demonstrate the continued interest of investors in the telehealth industry. The telehealth industry is poised for continued growth in the years to come, as it provides a convenient and affordable way to deliver healthcare to patients. Engage with the HealthTech Community HealthTech M&A Newsletter from Nelson Advisors - Market Insights & Analysis for Founders & Investors. Subscribe today! https://lnkd.in/e5hTp_xb HealthTech M&A Advisory by Founders for Founders, Owners & Investors. Buy Side, Sell Side, Growth and Strategy mandates - Email lloyd@nelsonadvisors.co.uk HealthTech Thought Leadership from Nelson Advisors - Industry Insights & Analysis for Founders, Owners & Investors. Visit https://www.healthcare.digital Telehealth Trend 1: Gastrointestinal care Telehealth is the use of telecommunications technology to provide medical care from a distance. This can include virtual visits with doctors, nurses, and other healthcare providers. Telehealth can be used for a variety of medical conditions, including gastrointestinal (GI) care. There are a number of benefits to using telehealth for GI care. First, it can provide patients with convenient and affordable access to care. Patients can see a provider from the comfort of their own homes, without having to travel to a clinic or hospital. This can be especially beneficial for patients who live in rural areas or who have difficulty traveling. Second, telehealth can help to improve patient satisfaction. Patients who use telehealth for GI care often report being more satisfied with their care than patients who see providers in person. This is likely due to the convenience and flexibility of telehealth, as well as the fact that patients feel more comfortable talking about sensitive GI issues with a provider in a private setting. Third, telehealth can help to improve the quality of GI care. Providers who use telehealth have access to the same diagnostic tools and resources as providers who see patients in person. This means that patients can receive the same level of care, regardless of whether they see a provider in person or virtually. In addition to the benefits for patients, telehealth also has benefits for providers. Providers who use telehealth can see more patients in a day, which can help to improve their productivity and efficiency. Telehealth can also help to reduce healthcare costs, as it can eliminate the need for patients to travel to clinics or hospitals for care. Overall, telehealth is a valuable tool for providing GI care. It can provide patients with convenient, affordable, and high-quality care. Providers who use telehealth can see more patients in a day and reduce healthcare costs. As the telehealth industry continues to grow, it is likely that telehealth will become an increasingly common method for providing GI care. Here are some examples of telehealth services that can be used for GI care: Virtual visits with a gastroenterologist: Patients can see a gastroenterologist online for a variety of GI conditions, such as irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and acid reflux disease. Telehealth monitoring: Patients can use telehealth devices to monitor their GI symptoms and share the data with their provider. This can help providers to track patients' progress and make adjustments to treatment plans as needed. Telehealth education: Providers can use telehealth to provide patients with education about GI conditions and treatment options. This can help patients to better understand their condition and make informed decisions about their care. There has been a significant increase in funding for telehealth gastrointestinal care in 2023. This is likely due to the growing demand for telehealth services and the potential for telehealth to improve outcomes and reduce costs for patients with GI conditions. Here are some examples of recent funding rounds for telehealth gastrointestinal care companies: Oshi Health raised $30 million in Series B funding in April 2023. The company provides virtual care for patients with GI conditions, such as irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and acid reflux disease. Vivante Health raised $16 million in Series A funding in March 2022. The company provides virtual care for patients with chronic GI conditions, such as gastroparesis and functional dyspepsia. Ayble Health raised $4.6 million in seed funding in October 2022. The company develops a digestive care platform that combines dietary guidance with behavioral health tools. Salvo Health raised $10.5 million in seed funding in July 2022. The company provides virtual care for patients with chronic gut conditions, such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). These are just a few examples of the recent funding rounds for telehealth gastrointestinal care companies. The telehealth gastrointestinal care industry is rapidly growing and investors are eager to support companies that are developing innovative solutions to improve patient care. Telehealth Trend 2: Mental Health Telehealth mental health is the use of telecommunications technology to provide mental health care from a distance. This can include virtual visits with therapists, psychiatrists, and other mental health professionals. Telehealth mental health can be used for a variety of mental health conditions, including depression, anxiety, and post-traumatic stress disorder (PTSD). There are a number of benefits to using telehealth for mental health care. First, it can provide patients with convenient and affordable access to care. Patients can see a mental health professional from the comfort of their own homes, without having to travel to a clinic or hospital. This can be especially beneficial for patients who live in rural areas or who have difficulty traveling. Second, telehealth can help to improve patient satisfaction. Patients who use telehealth for mental health care often report being more satisfied with their care than patients who see mental health professionals in person. This is likely due to the convenience and flexibility of telehealth, as well as the fact that patients feel more comfortable talking about sensitive mental health issues with a mental health professional in a private setting. Third, telehealth can help to improve the quality of mental health care. Mental health professionals who use telehealth have access to the same diagnostic tools and resources as mental health professionals who see patients in person. This means that patients can receive the same level of care, regardless of whether they see a mental health professional in person or virtually. In addition to the benefits for patients, telehealth also has benefits for mental health professionals. Mental health professionals who use telehealth can see more patients in a day, which can help to improve their productivity and efficiency. Telehealth can also help to reduce healthcare costs, as it can eliminate the need for patients to travel to clinics or hospitals for care. Overall, telehealth is a valuable tool for providing mental health care. It can provide patients with convenient, affordable, and high-quality care. Mental health professionals who use telehealth can see more patients in a day and reduce healthcare costs. As the telehealth industry continues to grow, it is likely that telehealth will become an increasingly common method for providing mental health care. Here are some examples of telehealth services that can be used for mental health care: Virtual visits with a therapist: Patients can see a therapist online for a variety of mental health conditions, such as depression, anxiety, and PTSD. Telehealth therapy groups: Patients can participate in therapy groups online with other patients who are experiencing similar challenges. This can be a valuable way for patients to connect with others and receive support. Telehealth medication management: Patients can see a psychiatrist online to discuss their medication and make adjustments as needed. Telehealth education: Mental health professionals can use telehealth to provide patients with education about mental health conditions and treatment options. This can help patients to better understand their condition and make informed decisions about their care. There has been a significant increase in funding for telehealth mental health in 2023. This is likely due to the growing demand for telehealth services and the potential for telehealth to improve outcomes and reduce costs for patients with mental health conditions. Here are some examples of recent funding rounds for telehealth mental health companies in 2023: BetterHelp raised $200 million in Series F funding in January 2023. The company provides online therapy to patients with a variety of mental health conditions. Headspace Health raised $100 million in Series D funding in February 2023. The company provides online therapy and mindfulness services to patients with a variety of mental health conditions. Talkspace raised $75 million in Series E funding in March 2023. The company provides online therapy to patients with a variety of mental health conditions. Cerebral raised $300 million in Series C funding in April 2023. The company provides online prescription medication for patients with mental health conditions. Regain raised $100 million in Series B funding in May 2023. The company provides online therapy to patients with a variety of mental health conditions. These are just a few examples of the recent funding rounds for telehealth mental health companies in 2023. The telehealth mental health industry is rapidly growing and investors are eager to support companies that are developing innovative solutions to improve patient care. The increased funding for telehealth mental health is a positive sign for patients with mental health conditions. It means that there are more options available for patients to receive convenient, affordable, and high-quality care. As the telehealth industry continues to grow, it is likely that telehealth will become an increasingly common method for providing mental health care. In addition to the companies mentioned above, there are a number of other telehealth mental health companies that are receiving funding in 2023. These companies are developing a variety of innovative solutions to improve the delivery of mental health care, such as: Virtual reality therapy: This type of therapy uses virtual reality to immerse patients in a safe and controlled environment where they can work through their trauma or other mental health challenges. Group therapy: This type of therapy allows patients to connect with others who are experiencing similar challenges and receive support from a therapist. Medication management: This type of therapy allows patients to see a psychiatrist online to discuss their medication and make adjustments as needed. Telehealth education: Mental health professionals can use telehealth to provide patients with education about mental health conditions and treatment options. This can help patients to better understand their condition and make informed decisions about their care. The telehealth mental health industry is rapidly growing and there are a number of innovative companies that are developing new ways to improve the delivery of mental health care. This is a positive sign for patients with mental health conditions, as it means that there are more options available for them to receive convenient, affordable, and high-quality care. Telehealth Trend 3: Weight management Telehealth weight management is the use of telecommunications technology to provide weight loss counseling and support from a distance. This can include virtual visits with a registered dietitian, certified personal trainer, or other weight loss specialist. Telehealth weight management can be a convenient and affordable way to lose weight, especially for people who live in rural areas or who have difficulty traveling to see a weight loss specialist in person. There are a number of benefits to using telehealth for weight management. First, it can provide patients with convenient and affordable access to care. Patients can see a weight loss specialist from the comfort of their own homes, without having to travel to a clinic or hospital. This can be especially beneficial for patients who live in rural areas or who have difficulty traveling. Second, telehealth can help to improve patient satisfaction. Patients who use telehealth for weight management often report being more satisfied with their care than patients who see weight loss specialists in person. This is likely due to the convenience and flexibility of telehealth, as well as the fact that patients feel more comfortable talking about sensitive weight loss issues with a weight loss specialist in a private setting. Third, telehealth can help to improve the quality of weight management care. Weight loss specialists who use telehealth have access to the same resources and tools as weight loss specialists who see patients in person. This means that patients can receive the same level of care, regardless of whether they see a weight loss specialist in person or virtually. In addition to the benefits for patients, telehealth also has benefits for weight loss specialists. Weight loss specialists who use telehealth can see more patients in a day, which can help to improve their productivity and efficiency. Telehealth can also help to reduce healthcare costs, as it can eliminate the need for patients to travel to clinics or hospitals for care. Overall, telehealth is a valuable tool for weight management. It can provide patients with convenient, affordable, and high-quality care. Weight loss specialists who use telehealth can see more patients in a day and reduce healthcare costs. As the telehealth industry continues to grow, it is likely that telehealth will become an increasingly common method for providing weight management care. Here are some examples of telehealth services that can be used for weight management: Virtual visits with a registered dietitian: Registered dietitians can provide patients with education about nutrition and weight loss, as well as help them to develop personalized meal plans. Virtual visits with a certified personal trainer: Certified personal trainers can provide patients with guidance on exercise and fitness, as well as help them to create a safe and effective exercise routine. Telehealth support groups: Telehealth support groups can provide patients with a community of people who are also trying to lose weight. This can be a valuable source of support and motivation. Telehealth education: Weight loss specialists can use telehealth to provide patients with education about weight loss and healthy living. This can help patients to better understand their condition and make informed decisions about their care. There has been a significant increase in funding for telehealth weight management in 2023. This is likely due to the growing demand for telehealth services and the potential for telehealth to improve outcomes and reduce costs for patients with obesity. Here are some examples of recent funding rounds for telehealth weight management companies in 2023: Calibrate raised $125 million in Series C funding in January 2023. The company provides a digital weight loss program that combines medication, including GLP-1 drugs, with behavior change delivered through a proprietary intensive lifestyle intervention. Virta Health raised $100 million in Series D funding in March 2023. The company provides a virtual diabetes prevention program that uses a combination of telemedicine, digital tools, and coaching to help patients lose weight and improve their metabolic health. Noom raised $50 million in Series E funding in May 2023. The company provides a weight loss program that uses a combination of cognitive behavioral therapy, personalized meal plans, and exercise tracking to help patients lose weight and keep it off. FoundMyFitness raised $25 million in Series A funding in June 2023. The company provides a personalized weight loss program that uses genetic testing, blood testing, and other data to create a customised plan for each patient. Wellory raised $10 million in Series A funding in July 2023. The company provides a weight loss program that uses a combination of telemedicine, digital tools, and coaching to help patients lose weight and improve their metabolic health. These are just a few examples of the recent funding rounds for telehealth weight management companies in 2023. The telehealth weight management industry is rapidly growing and investors are eager to support companies that are developing innovative solutions to improve patient care. The increased funding for telehealth weight management is a positive sign for patients with obesity. It means that there are more options available for patients to receive convenient, affordable, and high-quality care. As the telehealth industry continues to grow, it is likely that telehealth will become an increasingly common method for providing weight management care. In addition to the companies mentioned above, there are a number of other telehealth weight management companies that are receiving funding in 2023. These companies are developing a variety of innovative solutions to improve the delivery of weight loss care, such as: Virtual reality therapy: This type of therapy uses virtual reality to immerse patients in a safe and controlled environment where they can work through their food addiction or other weight loss challenges. Group therapy: This type of therapy allows patients to connect with others who are experiencing similar challenges and receive support from a therapist. Medication management: This type of therapy allows patients to see a doctor online to discuss their medication and make adjustments as needed. Telehealth education: Weight loss specialists can use telehealth to provide patients with education about weight loss and healthy living. This can help patients to better understand their condition and make informed decisions about their care. The telehealth weight management industry is rapidly growing and there are a number of innovative companies that are developing new ways to improve the delivery of weight loss care. This is a positive sign for patients with obesity, as it means that there are more options available for them to receive convenient, affordable, and high-quality care. Telehealth Trend 4: Women's Health Telehealth women's health is the use of telecommunications technology to provide women's health care from a distance. This can include virtual visits with gynecologists, nurse practitioners, and other women's health providers. Telehealth women's health can be a convenient and affordable way to receive women's health care, especially for women who live in rural areas or who have difficulty traveling to see a women's health provider in person. There are a number of benefits to using telehealth for women's health care. First, it can provide patients with convenient and affordable access to care. Patients can see a women's health provider from the comfort of their own homes, without having to travel to a clinic or hospital. This can be especially beneficial for women who live in rural areas or who have difficulty traveling. Second, telehealth can help to improve patient satisfaction. Patients who use telehealth for women's health care often report being more satisfied with their care than patients who see women's health providers in person. This is likely due to the convenience and flexibility of telehealth, as well as the fact that patients feel more comfortable talking about sensitive women's health issues with a women's health provider in a private setting. Third, telehealth can help to improve the quality of women's health care. Women's health providers who use telehealth have access to the same resources and tools as women's health providers who see patients in person. This means that patients can receive the same level of care, regardless of whether they see a women's health provider in person or virtually. In addition to the benefits for patients, telehealth also has benefits for women's health providers. Women's health providers who use telehealth can see more patients in a day, which can help to improve their productivity and efficiency. Telehealth can also help to reduce healthcare costs, as it can eliminate the need for patients to travel to clinics or hospitals for care. Overall, telehealth is a valuable tool for women's health care. It can provide patients with convenient, affordable, and high-quality care. Women's health providers who use telehealth can see more patients in a day and reduce healthcare costs. As the telehealth industry continues to grow, it is likely that telehealth will become an increasingly common method for providing women's health care. Here are some examples of telehealth services that can be used for women's health care: Virtual visits with a gynecologist: Gynecologists can provide patients with care for a variety of women's health issues, including contraception, pregnancy care, and menopause. Telehealth education: Women's health providers can use telehealth to provide patients with education about women's health issues and treatment options. This can help patients to better understand their condition and make informed decisions about their care. Telehealth support groups: Telehealth support groups can provide patients with a community of women who are also facing similar challenges. This can be a valuable source of support and motivation. There has been a significant increase in funding for telehealth women's health in 2023. This is likely due to the growing demand for telehealth services and the potential for telehealth to improve outcomes and reduce costs for women's health conditions. Here are some examples of recent funding rounds for telehealth women's health companies in 2023: Kindbody raised $160 million in Series C funding in January 2023. The company provides a virtual fertility clinic that offers a suite of services, including egg freezing, IVF, and miscarriage support. Modern Fertility raised $100 million in Series C funding in February 2023. The company provides at-home fertility testing kits and personalized coaching. Clara Health raised $75 million in Series B funding in March 2023. The company provides virtual care for women with chronic conditions, such as diabetes and hypertension. Prairie Women's Health raised $50 million in Series A funding in April 2023. The company provides virtual care for women's health conditions, such as pelvic pain and endometriosis. Maven raised $30 million in Series C funding in May 2023. The company provides virtual care for women during pregnancy and postpartum. These are just a few examples of the recent funding rounds for telehealth women's health companies in 2023. The telehealth women's health industry is rapidly growing and investors are eager to support companies that are developing innovative solutions to improve patient care. The increased funding for telehealth women's health is a positive sign for women's health. It means that there are more options available for women to receive convenient, affordable, and high-quality care. As the telehealth industry continues to grow, it is likely that telehealth will become an increasingly common method for providing women's health care. In addition to the companies mentioned above, there are a number of other telehealth women's health companies that are receiving funding in 2023. These companies are developing a variety of innovative solutions to improve the delivery of women's health care, such as: Virtual reality therapy: This type of therapy uses virtual reality to immerse patients in a safe and controlled environment where they can work through their pain or other women's health challenges. Group therapy: This type of therapy allows patients to connect with others who are experiencing similar challenges and receive support from a therapist. Medication management: This type of therapy allows patients to see a doctor online to discuss their medication and make adjustments as needed. Telehealth education: Women's health providers can use telehealth to provide patients with education about women's health issues and treatment options. This can help patients to better understand their condition and make informed decisions about their care. The telehealth women's health industry is rapidly growing and there are a number of innovative companies that are developing new ways to improve the delivery of women's health care. This is a positive sign for women's health, as it means that there are more options available for women to receive convenient, affordable, and high-quality care. Telehealth Trend 5: Wound Care Telehealth wound care is the use of telecommunications technology to provide wound care from a distance. This can include virtual visits with wound care nurses, doctors, and other healthcare providers. Telehealth wound care can be a convenient and affordable way to receive wound care, especially for patients who live in rural areas or who have difficulty traveling to see a wound care provider in person. There are a number of benefits to using telehealth for wound care. First, it can provide patients with convenient and affordable access to care. Patients can see a wound care provider from the comfort of their own homes, without having to travel to a clinic or hospital. This can be especially beneficial for patients who live in rural areas or who have difficulty traveling. Second, telehealth can help to improve patient satisfaction. Patients who use telehealth for wound care often report being more satisfied with their care than patients who see wound care providers in person. This is likely due to the convenience and flexibility of telehealth, as well as the fact that patients feel more comfortable talking about their wound care needs with a wound care provider in a private setting. Third, telehealth can help to improve the quality of wound care. Wound care providers who use telehealth have access to the same resources and tools as wound care providers who see patients in person. This means that patients can receive the same level of care, regardless of whether they see a wound care provider in person or virtually. In addition to the benefits for patients, telehealth also has benefits for wound care providers. Wound care providers who use telehealth can see more patients in a day, which can help to improve their productivity and efficiency. Telehealth can also help to reduce healthcare costs, as it can eliminate the need for patients to travel to clinics or hospitals for care. Overall, telehealth is a valuable tool for wound care. It can provide patients with convenient, affordable, and high-quality care. Wound care providers who use telehealth can see more patients in a day and reduce healthcare costs. As the telehealth industry continues to grow, it is likely that telehealth will become an increasingly common method for providing wound care. Here are some examples of telehealth services that can be used for wound care: Virtual visits with a wound care nurse: Wound care nurses can assess wounds, provide dressing changes, and prescribe medications. Telehealth education: Wound care providers can use telehealth to provide patients with education about wound care and treatment options. This can help patients to better understand their condition and make informed decisions about their care. Telehealth support groups: Telehealth support groups can provide patients with a community of people who are also living with chronic wounds. This can be a valuable source of support and motivation. There has been a significant increase in funding for telehealth wound care in 2023. This is likely due to the growing demand for telehealth services and the potential for telehealth to improve outcomes and reduce costs for patients with chronic wounds. Here are some examples of recent funding rounds for telehealth wound care companies in 2023: Oshi Health raised $30 million in Series B funding in April 2023. The company provides virtual care for patients with chronic wounds, such as diabetic foot ulcers and pressure sores. Vivante Health raised $16 million in Series A funding in March 2023. The company provides virtual care for patients with chronic GI conditions, such as gastroparesis and functional dyspepsia. Ayble Health raised $4.6 million in seed funding in October 2022. The company develops a digestive care platform that combines dietary guidance with behavioral health tools. Salvo Health raised $10.5 million in seed funding in July 2022. The company provides virtual care for patients with chronic gut conditions, such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). These are just a few examples of the recent funding rounds for telehealth wound care companies in 2023. The telehealth wound care industry is rapidly growing and investors are eager to support companies that are developing innovative solutions to improve patient care. The increased funding for telehealth wound care is a positive sign for patients with chronic wounds. It means that there are more options available for patients to receive convenient, affordable, and high-quality care. As the telehealth industry continues to grow, it is likely that telehealth will become an increasingly common method for providing wound care. In addition to the companies mentioned above, there are a number of other telehealth wound care companies that are receiving funding in 2023. These companies are developing a variety of innovative solutions to improve the delivery of wound care, such as: Virtual reality therapy: This type of therapy uses virtual reality to immerse patients in a safe and controlled environment where they can work through their pain or other wound care challenges. Group therapy: This type of therapy allows patients to connect with others who are experiencing similar challenges and receive support from a therapist. Medication management: This type of therapy allows patients to see a doctor online to discuss their medication and make adjustments as needed. Telehealth education: Wound care providers can use telehealth to provide patients with education about wound care and treatment options. This can help patients to better understand their condition and make informed decisions about their care. The telehealth wound care industry is rapidly growing and there are a number of innovative companies that are developing new ways to improve the delivery of wound care. This is a positive sign for patients with chronic wounds, as it means that there are more options available for patients to receive convenient, affordable, and high-quality care. Engage with the HealthTech Community HealthTech M&A Newsletter from Nelson Advisors - Market Insights & Analysis for Founders & Investors. Subscribe today! https://lnkd.in/e5hTp_xb HealthTech M&A Advisory by Founders for Founders, Owners & Investors. Buy Side, Sell Side, Growth and Strategy mandates - Email lloyd@nelsonadvisors.co.uk HealthTech Thought Leadership from Nelson Advisors - Industry Insights & Analysis for Founders, Owners & Investors. Visit https://www.healthcare.digital

Exec Summary: Babylon's UK business needs to find a new home, so what exactly is on offer, what does Babylon UK offer a new buyer in terms of benefits to the NHS and patients to build on? Babylon's services are available to NHS patients through a number of different channels, including: The Babylon app: The Babylon app is available to download for free on iOS and Android devices. The NHS App: The NHS App is available to download for free on iOS and Android devices. Babylon's services are integrated into the NHS App, so patients can access them from the same place where they access other NHS services. The Babylon website: Babylon's website is available at https://www.babylonhealth.com/. Patients can access Babylon's services through the website, but they will need to create an account first. Some of the benefits of Babylon UK's services for the NHS and patients: Reduced waiting times: Babylon UK's services can help to reduce waiting times for NHS appointments. This is because patients can book video consultations and chat with doctors outside of regular office hours. Improved access to care: Babylon UK's services can help to improve access to care for patients who live in rural areas or who have difficulty getting to a doctor's office. This is because patients can access Babylon's services through their smartphones or computers. Better quality of care: Babylon UK's services can help to improve the quality of care patients receive. This is because Babylon's doctors have access to a wider range of data about patients, including their medical history, lifestyle habits, and genetic information. Reduced costs: Babylon UK's services can help to reduce the costs of healthcare for the NHS. This is because Babylon's services can help to reduce the number of unnecessary hospital admissions and GP visits. Overall, Babylon UK's services offer a number of benefits for the NHS and patients. The company's services can help to reduce waiting times, improve access to care, and improve the quality of care patients receive. Babylon UK's services can also help to reduce the costs of healthcare for the NHS. So the million dollar question is, who could see a strategic fit to acquire Babylon's UK business? Five companies come to mind for a wide range of reasons: 1) Operose Health 2) Huma 3) Modality Partnership 4) BUPA 5) Aurelius/McKesson UK Ultimately, the decision of who will acquire Babylon's UK business will depend on a number of factors, including the price that is offered, the strategic fit between the buyer and Babylon, and the regulatory approval process. Engage with the HealthTech Community HealthTech M&A Newsletter from Nelson Advisors - Market Insights & Analysis for Founders & Investors. Subscribe today! https://lnkd.in/e5hTp_xb HealthTech M&A Advisory by Founders for Founders, Owners & Investors. Buy Side, Sell Side, Growth and Strategy mandates - Email lloyd@nelsonadvisors.co.uk HealthTech Thought Leadership from Nelson Advisors - Industry Insights & Analysis for Founders, Owners & Investors. Visit https://www.healthcare.digital Operose Health Rationale for acquiring Babylon's UK business: increase primary care market share, familiar with the business as an investor via Centene their parent company, digital first GP offering is a competitive advantage, Babylon's 100k patients adds to existing 640k patient base Operose Health is a UK-based primary care provider that was formed in 2020 by Centene Corporation, a US health insurer. Operose Health owns and operates a number of GP surgeries and other primary care facilities in England. It also offers a range of digital healthcare services, such as video consultations with doctors and access to medical records online. Operose Health is one of the largest primary care providers in the UK, with over 640,000 patients. It is also one of the most innovative primary care providers in the UK, with a strong focus on using technology to improve the quality of care it provides. Operose Health has been criticized by some for its reliance on private equity funding. However, the company has defended its business model, arguing that it allows it to invest in new technologies and services that would not be possible if it were funded by the government. Operose Health is likely to play an increasingly important role in the UK healthcare system in the years to come. It is well-positioned to benefit from the growing demand for digital healthcare and its focus on innovation is likely to help it to stay ahead of the competition. Here are some additional details about Operose Health: Operose Health is headquartered in Little Chalfont, England. Operose Health was formed in 2020 by Centene Corporation, a US health insurer. Operose Health owns and operates a number of GP surgeries and other primary care facilities in England. Operose Health also offers a range of digital healthcare services, such as video consultations with doctors and access to medical records online. Operose Health is one of the largest primary care providers in the UK, with over 640,000 patients. Operose Health is also one of the most innovative primary care providers in the UK, with a strong focus on using technology to improve the quality of care it provides. Operose Health has been criticized by some for its reliance on private equity funding. However, the company has defended its business model, arguing that it allows it to invest in new technologies and services that would not be possible if it were funded by the government. Operose Health is likely to play an increasingly important role in the UK healthcare system in the years to come. It is well-positioned to benefit from the growing demand for digital healthcare and its focus on innovation is likely to help it to stay ahead of the competition. Huma Rationale for acquiring Babylon's UK business: fits with primary care acquisition strategy having already bought iPlato, fits with AI technology acquisition strategy having already bought Biobeats and Tarilian Laser Technologies, acquihire of developers and ML engineers Huma (previously known as Medopad) is a British healthcare technology company based in London, UK. It produces applications that integrate health data from existing hospital databases as well as patient wearables and other mobile devices and securely transmits it for use by doctors. Huma was founded in 2011 by Dan Vahdat and Rich Khatib. The company's name was changed to Huma in 2020 to reflect its mission to "democratize healthcare" and make it more accessible to everyone. Huma's platform allows doctors to remotely monitor patients with chronic diseases, such as diabetes and heart disease. It also provides patients with access to their medical records and allows them to book appointments with doctors online. Huma has been praised for its innovative technology and its potential to improve the quality of care for patients. However, the company has also been criticized for its high costs and for its reliance on data from wearable devices, which some experts believe is not always accurate. Huma is still a relatively young company, but it has the potential to revolutionize the healthcare industry. The company is well-funded and has a strong team of experts. If Huma can overcome the challenges it faces, it could become a major player in the global healthcare market. Here are some of Huma's products and services: Remote patient monitoring: Huma's remote patient monitoring platform allows doctors to remotely monitor patients with chronic diseases, such as diabetes and heart disease. This can help to improve the quality of care for patients and reduce the number of hospital visits. Online medical records: Huma's online medical records platform allows patients to access their medical records from anywhere. This can help patients to better understand their health and to communicate with their doctors more effectively. Appointment booking: Huma's appointment booking platform allows patients to book appointments with doctors online. This can save patients time and hassle. Wearable devices: Huma partners with a number of wearable device manufacturers to collect data from patients' wearable devices. This data can be used to improve the accuracy of Huma's remote patient monitoring platform and to provide patients with personalized health insights. Huma is a rapidly growing company with a bright future. The company is well-positioned to benefit from the growing demand for digital healthcare and its focus on innovation is likely to help it to stay ahead of the competition. Modality Partnership Rationale for acquiring Babylon's UK business: increase primary care market share, digital first GP offering is a competitive advantage, Babylon's 100k patients adds to existing 400k patient base, add ML and developer expertise to traditional primary care business Modality Partnership is a large GP partnership formed in 2009. It is one of England’s largest super-practices, with over 400,000 patients. Modality Partnership operates primary health care and community health services across the country. Modality Partnership was founded by a group of GPs who were dissatisfied with the current state of primary care in the UK. They believed that primary care needed to be more innovative and patient-centric. Modality Partnership was created to provide a new model of primary care that is focused on prevention and early intervention. Modality Partnership has a number of innovative practices, including: Virtual wards: Modality Partnership operates a number of virtual wards, which allow patients to be treated remotely by a team of doctors and nurses. This can help to reduce the number of hospital admissions and improve the quality of care for patients. Community health hubs: Modality Partnership operates a number of community health hubs, which provide a range of health and social care services in one place. This can make it easier for patients to access the care they need. Personalized health plans: Modality Partnership creates personalized health plans for each patient. These plans are based on the patient's individual needs and goals. This can help patients to take control of their health and improve their overall health outcomes. Modality Partnership has been praised for its innovative practices and its focus on patient-centered care. The company has been recognized by a number of organizations, including the King's Fund and the NHS Confederation. Modality Partnership is well-positioned to lead the way in the transformation of primary care in the UK. The company has a strong track record of innovation and a commitment to patient-centered care. If Modality Partnership can continue to grow and scale, it could have a major impact on the way that primary care is delivered in the UK. BUPA Rationale for acquiring Babylon's UK business: increase primary care market share, familiar with the business as a partner for the last 5 years, digital first GP offering is a competitive advantage, add ML and developer expertise to traditional insurance business Bupa UK is the UK division of Bupa, a global health and care company with over 30 million customers worldwide. Bupa UK provides a range of health insurance, healthcare services, and products to individuals and businesses in the UK. Bupa UK was founded in 1947 as the British United Provident Association. The company was formed by a group of local provident associations and hospital contributory schemes. Bupa UK initially offered health insurance to its members, but it has since expanded its offerings to include a range of healthcare services, such as: GP care: Bupa UK provides GP care to its members through a network of over 2,000 GP practices. Opens in a new window gpcare.org.uk GP care logo Specialist care: Bupa UK provides specialist care to its members through a network of over 100 hospitals and clinics. Opens in a new window www.rbhh-specialistcare.co.uk Specialist care logo Dental care: Bupa UK provides dental care to its members through a network of over 3,000 dentists. Opens in a new window www.freepik.com Dental care logo Vision care: Bupa UK provides vision care to its members through a network of over 1,000 opticians. Opens in a new window www.vecteezy.com Vision care logo Other health services: Bupa UK also provides a range of other health services, such as: Travel insurance: Bupa UK provides travel insurance to its members to cover them for medical expenses while they are abroad. Critical illness cover: Bupa UK provides critical illness cover to its members to pay out a lump sum if they are diagnosed with a critical illness. Income protection: Bupa UK provides income protection to its members to pay out a monthly income if they are unable to work due to illness or injury. Bupa UK is a leading provider of health insurance and healthcare services in the UK. The company has a strong track record of innovation and a commitment to providing high-quality care to its customers. Bupa UK is well-positioned to continue to grow and expand its offerings in the years to come. Aurelius Group/McKesson UK Rationale for acquiring Babylon's UK business: increase primary care market share, another 100k patients to drive prescriptions through Lloyd's Pharmacy, add ML and developer expertise to traditional wholesale pharmaceuticals and medical supplies business Aurelius Group is a European investment firm that specializes in buying and restructuring underperforming companies. The company was founded in 2005 by Dirk Markus and Gert Purkert. Aurelius Group has a team of over 100 investment professionals with experience in a range of industries, including healthcare, industrials, and technology. The company has offices in Germany, Luxembourg, the UK, and the US. Aurelius Group has a track record of success in restructuring companies. The company has invested in over 100 companies and has generated over €10 billion in value for its investors. Aurelius Group is a leading investor in the European healthcare sector. The company has a track record of success in restructuring companies and has a strong team of investment professionals. Aurelius Group is well-positioned to continue to invest in the healthcare sector and to help companies improve their performance. Aurelius Group acquired McKesson UK in November 2021 in a deal worth £477 million. The acquisition was Aurelius Group's largest ever deal in the UK. McKesson UK is a leading provider of wholesale pharmaceuticals and medical supplies to pharmacies, hospitals, and other healthcare providers in the UK. The company has a turnover of over £2 billion and employs over 2,000 people. Aurelius Group said that it acquired McKesson UK to expand its presence in the healthcare sector. The company said that it plans to invest in McKesson UK to grow the business and to improve its efficiency. The acquisition of McKesson UK is a major coup for Aurelius Group. The company has now established itself as a major player in the UK healthcare sector. Aurelius Group is likely to continue to invest in the healthcare sector in the years to come. Here are some of the reasons why Aurelius Group acquired McKesson UK: McKesson UK is a leading provider of wholesale pharmaceuticals and medical supplies to pharmacies, hospitals, and other healthcare providers in the UK. This gives Aurelius Group a strong foothold in the UK healthcare market. McKesson UK has a turnover of over £2 billion and employs over 2,000 people. This gives Aurelius Group a significant scale in the UK healthcare market. Aurelius Group plans to invest in McKesson UK to grow the business and to improve its efficiency. This will make McKesson UK a more attractive investment for Aurelius Group. The acquisition of McKesson UK is a major coup for Aurelius Group. The company has now established itself as a major player in the UK healthcare sector. Aurelius Group is likely to continue to invest in the healthcare sector in the years to come. Engage with the HealthTech Community HealthTech M&A Newsletter from Nelson Advisors - Market Insights & Analysis for Founders & Investors. Subscribe today! https://lnkd.in/e5hTp_xb HealthTech M&A Advisory by Founders for Founders, Owners & Investors. Buy Side, Sell Side, Growth and Strategy mandates - Email lloyd@nelsonadvisors.co.uk HealthTech Thought Leadership from Nelson Advisors - Industry Insights & Analysis for Founders, Owners & Investors. Visit https://www.healthcare.digital

Exec Summary: Value-based care (VBC) is a healthcare payment and delivery model that rewards providers for delivering high-quality, efficient care that improves patient outcomes. VBC is based on the idea that the best way to reduce healthcare costs is to improve the quality of care and keep people healthier. In traditional fee-for-service (FFS) healthcare, providers are paid for each service they provide, regardless of the quality of care or the patient's outcome. This can lead to providers providing unnecessary or low-quality care in order to maximize their profits. VBC, on the other hand, ties payments to the quality of care and the patient's outcome. This means that providers are rewarded for keeping patients healthy and preventing them from getting sick in the first place. According to a report by Rock Health, venture capital investment in value-based care (VBC) companies in the United States reached $10.7 billion in the 12 months ending March 2023, up from $7.7 billion in the previous 12 months. This represents a 39% increase in investment. Venture capitalists are increasingly investing in VBC companies that are developing new models of care, technologies, and solutions that can help to make this vision a reality. Engage with the HealthTech Community HealthTech M&A Newsletter from Nelson Advisors - Market Insights & Analysis for Founders & Investors. Subscribe today! https://lnkd.in/e5hTp_xb HealthTech M&A Advisory by Founders for Founders, Owners & Investors. Buy Side, Sell Side, Growth and Strategy mandates - Email lloyd@nelsonadvisors.co.uk HealthTech Thought Leadership from Nelson Advisors - Industry Insights & Analysis for Founders, Owners & Investors. Visit https://www.healthcare.digital Introduction to Value-based care (VBC) There are many different types of VBC models, but they all share some common features. These features include: A focus on quality and outcomes: VBC models measure the quality of care and the patient's outcome, and providers are rewarded for meeting or exceeding these measures. A shared risk approach: VBC models typically involve a shared risk approach, in which providers and payers share the financial risk for the patient's care. This incentivizes providers to keep patients healthy and prevent them from getting sick. A focus on prevention: VBC models emphasize prevention, as this is the best way to keep people healthy and reduce healthcare costs. A focus on coordination of care: VBC models require providers to coordinate care across different settings, such as hospitals, clinics, and home health agencies. This ensures that patients receive the care they need, when they need it. VBC is still a relatively new approach to healthcare, but it has the potential to improve the quality of care, reduce healthcare costs, and improve the patient experience. Here are some of the benefits of value-based care: Improved quality of care: VBC models incentivize providers to focus on quality and outcomes, which can lead to improved patient health. Reduced healthcare costs: VBC models can help to reduce healthcare costs by preventing illness and keeping people healthy. Improved patient experience: VBC models can improve the patient experience by providing more coordinated and patient-centered care. However, there are also some challenges to implementing VBC, such as: The need for data and measurement: VBC models require a lot of data and measurement in order to track quality and outcomes. The need for collaboration: VBC models require collaboration between providers, payers, and patients. The need for a change in culture: VBC requires a change in culture from a focus on volume to a focus on quality and outcomes. Despite these challenges, value-based care is a promising approach to healthcare that has the potential to improve the quality of care, reduce healthcare costs, and improve the patient experience. Value-based care (VBC) investment: Venture capital investment into value-based care (VBC) has been growing rapidly in recent years. According to McKinsey, private capital inflows to value-based care companies increased more than fourfold from 2019 to 2021, while new hospital construction—a proxy for investment in legacy-care delivery models—held flat. There are a few reasons for this investment boom. First, there is a growing recognition that the traditional fee-for-service (FFS) healthcare model is not sustainable. FFS incentivizes providers to provide more care, regardless of the quality or the patient's outcome. This can lead to higher healthcare costs and poorer patient outcomes. Second, there is increasing pressure from payers, such as insurers and employers, to move to value-based care models. Payers are looking for ways to reduce healthcare costs and improve the quality of care. VBC models offer a potential solution to these challenges. Third, there are a number of innovative technologies and solutions that can support VBC. These technologies can help to improve the coordination of care, track patient outcomes, and provide preventive care. As a result of these factors, venture capitalists are increasingly investing in VBC companies. These companies are developing new models of care, technologies, and solutions that can help to improve the quality of care, reduce healthcare costs, and improve the patient experience. Some of the key areas of venture capital investment in VBC include: Population health management: This involves using data and analytics to track the health of populations and identify people who are at risk for developing chronic diseases. Care coordination: This involves connecting patients with the care they need, when they need it, across different settings. Preventive care: This involves providing services that can help to prevent illness and keep people healthy. Digital health: This involves using technology to improve the delivery of care, such as through telehealth and remote patient monitoring. Value-based care enablement: This involves providing services to help providers transition to value-based care, such as risk management and data analytics. The venture capital investment boom in VBC is a sign of the growing momentum behind this approach to healthcare. VBC has the potential to improve the quality of care, reduce healthcare costs, and improve the patient experience. As a result, venture capitalists are increasingly investing in VBC companies that are developing new models of care, technologies, and solutions that can help to make this vision a reality. Venture capital investment in value-based care (VBC) companies According to a report by Rock Health, venture capital investment in value-based care (VBC) companies in the United States reached $10.7 billion in the 12 months ending March 2023, up from $7.7 billion in the previous 12 months. This represents a 39% increase in investment. The report also found that the number of VBC deals also increased, from 175 in the previous 12 months to 210 in the most recent 12 months. The report attributed the increase in investment to a number of factors, including: The growing recognition that the traditional fee-for-service (FFS) healthcare model is not sustainable. Increasing pressure from payers, such as insurers and employers, to move to value-based care models. The availability of new technologies and solutions that can support VBC. The report also found that the most active areas of investment in VBC were: Population health management: This involves using data and analytics to track the health of populations and identify people who are at risk for developing chronic diseases. Care coordination: This involves connecting patients with the care they need, when they need it, across different settings. Preventive care: This involves providing services that can help to prevent illness and keep people healthy. Digital health: This involves using technology to improve the delivery of care, such as through telehealth and remote patient monitoring. Value-based care enablement: This involves providing services to help providers transition to value-based care, such as risk management and data analytics. The report concluded that the investment boom in VBC is a sign of the growing momentum behind this approach to healthcare. VBC has the potential to improve the quality of care, reduce healthcare costs, and improve the patient experience. As a result, venture capitalists are increasingly investing in VBC companies that are developing new models of care, technologies, and solutions that can help to make this vision a reality. Final thoughts: The future of value-based care (VBC) is bright. VBC is gaining momentum as a way to improve the quality of care, reduce healthcare costs, and improve the patient experience. Here are some of the key trends that are expected to drive the future of VBC in the next few years: Increased investment in VBC: Venture capital investment in VBC is expected to continue to grow in the coming years. This investment will be used to develop new models of care, technologies, and solutions that can help to improve the quality of care, reduce healthcare costs, and improve the patient experience. Broader adoption of VBC: VBC is still a relatively new approach to healthcare, but it is gaining traction. More and more providers, payers, and patients are adopting VBC models. This trend is expected to continue in the coming years. Development of new technologies: New technologies, such as artificial intelligence, machine learning, and big data analytics, are being developed to support VBC. These technologies can help to improve the coordination of care, track patient outcomes, and provide preventive care. Focus on population health: VBC is increasingly focused on population health. This means that providers are working to improve the health of entire populations, rather than just individual patients. This approach can help to reduce healthcare costs and improve the overall health of the population. Alignment of incentives: One of the biggest challenges to VBC is aligning the incentives of providers, payers, and patients. This is being addressed through new payment models that reward providers for improving the quality of care and reducing healthcare costs. Overall, the future of VBC is bright. VBC has the potential to improve the quality of care, reduce healthcare costs, and improve the patient experience. As VBC continues to gain momentum, we can expect to see even more innovation and progress in the coming years. Here are some specific examples of how VBC is being implemented in the real world: The Centers for Medicare & Medicaid Services (CMS) has launched a number of VBC initiatives, such as the Medicare Shared Savings Program and the Accountable Care Organization (ACO) program. Private payers, such as insurers and employers, are also adopting VBC models. For example, UnitedHealthcare has a number of VBC programs, such as its OptumHealth program. Some providers are also taking the lead on VBC. For example, Kaiser Permanente has a number of VBC programs, such as its Permanente Medical Group. These are just a few examples of how VBC is being implemented in the real world. As VBC continues to gain momentum, we can expect to see even more innovation and progress in the coming years. Engage with the HealthTech Community HealthTech M&A Newsletter from Nelson Advisors - Market Insights & Analysis for Founders & Investors. Subscribe today! https://lnkd.in/e5hTp_xb HealthTech M&A Advisory by Founders for Founders, Owners & Investors. Buy Side, Sell Side, Growth and Strategy mandates - Email lloyd@nelsonadvisors.co.uk HealthTech Thought Leadership from Nelson Advisors - Industry Insights & Analysis for Founders, Owners & Investors. Visit https://www.healthcare.digital

Exec Summary: In today's market, there is a growing emphasis on value-based care, which means paying for healthcare based on the quality of care rather than the quantity of services provided. This is driving demand for HealthTech solutions that can help to improve patient outcomes and reduce costs. As a result, strategic HealthTech acquirers are increasingly looking for companies that can help them meet these challenges. Here are some specific areas of focus for strategic HealthTech acquirers in today's market: Digital health: This includes software for managing patient records, scheduling appointments, and providing remote care. Telehealth: This refers to the delivery of healthcare services remotely, such as through video conferencing. Wearable devices: These devices can be used to track patients' health data, such as heart rate, blood pressure, and blood sugar levels. AI and machine learning: These technologies can be used to analyze large amounts of data to identify patterns and trends that can help improve patient care. Genomics: This field studies the genetic makeup of individuals and can be used to develop personalized treatments for diseases. Engage with the HealthTech Community HealthTech M&A Newsletter from Nelson Advisors - Market Insights & Analysis for Founders & Investors. Subscribe today! https://lnkd.in/e5hTp_xb HealthTech M&A Advisory by Founders for Founders, Owners & Investors. Buy Side, Sell Side, Growth and Strategy mandates - Email lloyd@nelsonadvisors.co.uk HealthTech Thought Leadership from Nelson Advisors - Industry Insights & Analysis for Founders, Owners & Investors. Visit https://www.healthcare.digital What are strategic HealthTech acquirers looking for in today's market?: Strategic HealthTech acquirers are looking for a variety of things in today's market, top of the list are: Technology with the potential to disrupt the status quo. Acquirers are looking for technologies that have the potential to fundamentally change the way healthcare is delivered or received. This could include technologies that improve patient outcomes, reduce costs, or make healthcare more convenient. Companies with strong intellectual property (IP). IP is essential for protecting a company's innovations and ensuring its long-term success. Acquirers are looking for companies with strong IP portfolios that they can use to expand their own offerings or defend themselves against competition. A team of talented and experienced professionals. The success of any acquisition depends on the people involved. Acquirers are looking for companies with teams of talented and experienced professionals who can help them integrate the acquired company and achieve their strategic goals. A strong market opportunity. The healthcare industry is large and growing, and there are many opportunities for innovation. Acquirers are looking for companies that are well-positioned to capitalize on these opportunities. A good fit with the acquirer's culture and values. An acquisition is a big change for both companies involved. It is important that the acquirer and the acquired company have a good fit in terms of culture and values. This will help to ensure a smooth integration and a successful outcome for both parties. In addition to these factors, strategic healthtech acquirers are also looking for companies that have a strong growth potential, a clear competitive advantage, and a good reputation. Key trends driving strategic healthtech acquisitions: Here are some of the specific trends that are driving strategic healthtech acquisitions in today's market: The increasing demand for digital health solutions: The aging population and the growing prevalence of chronic diseases are driving the demand for digital health solutions. This is creating opportunities for healthtech companies that offer products and services that can improve the quality of care and reduce costs. The rise of artificial intelligence and machine learning: Artificial intelligence and machine learning are rapidly transforming the healthcare industry. These technologies are being used to develop new diagnostic tools, improve the efficiency of clinical workflows, and personalize treatment plans. The growing focus on preventive care: The healthcare industry is shifting its focus from reactive care to preventive care. This is creating opportunities for healthtech companies that offer products and services that can help people stay healthy. The increasing regulatory scrutiny: The healthcare industry is heavily regulated. This can make it difficult for healthtech companies to bring new products and services to market. However, it also creates opportunities for companies that can help healthcare organizations comply with regulations. Overall, the strategic healthtech acquisition market is very active. There are a number of factors driving this activity, including the increasing demand for digital health solutions, the rise of artificial intelligence and machine learning, the growing focus on preventive care, and the increasing regulatory scrutiny. Key priorities for strategic healthtech acquirers: The key priorities for strategic healthtech acquirers are: Growth: Strategic acquirers are looking for companies that can help them grow their businesses. This could mean acquiring companies that operate in new markets, offer new products or services, or have a strong customer base. Innovation: Strategic acquirers are also looking for companies that are innovative and can help them stay ahead of the competition. This could mean acquiring companies that are developing new technologies or have a strong track record of innovation. Market share: Strategic acquirers may also be looking to acquire companies that will give them a larger market share. This could be in a specific market or in the overall healthtech market. Competitive advantage: Strategic acquirers may also be looking to acquire companies that will give them a competitive advantage. This could be through access to new technologies, markets, or customers. Revenue: Strategic acquirers may also be looking to acquire companies that will generate additional revenue. This could be through the sale of products or services, or through the expansion of the acquirer's existing business. Profitability: Strategic acquirers may also be looking to acquire companies that are profitable. This could mean acquiring companies that have a strong track record of profitability or that have the potential to become profitable in the future. Exit strategy: Strategic acquirers may also have an exit strategy in mind, such as taking the acquired company public or selling it to another company. This will affect the type of company they are looking to acquire and the price they are willing to pay. Case Studies: strategic healthtech acquirers achieving their key priorities Here are some specific examples of how strategic healthtech acquirers have achieved their key priorities: Growth: In 2022, UnitedHealth Group acquired Change Healthcare for $13 billion. This acquisition will help UnitedHealth Group expand its reach into the healthcare IT market. Innovation: In 2021, Johnson & Johnson acquired Verb Surgical for $3.4 billion. This acquisition will give Johnson & Johnson access to Verb Surgical's robotic surgery technology. Market share: In 2020, CVS Health acquired Aetna for $69 billion. This acquisition gave CVS Health a larger market share in the healthcare insurance market. Economies of scale: In 2019, Abbott Laboratories acquired Alere for $5.3 billion. This acquisition helped Abbott Laboratories achieve economies of scale in the point-of-care diagnostics market. Diversification: In 2018, Medtronic acquired Covidien for $49.9 billion. This acquisition diversified Medtronic's business into the medical devices market. Talent: In 2017, Illumina acquired Verinata Health for $800 million. This acquisition gave Illumina access to Verinata Health's talent in the prenatal genetic testing market. Regulatory compliance: In 2016, Cerner acquired Athenahealth for $10.5 billion. This acquisition helped Cerner comply with the Health Insurance Portability and Accountability Act (HIPAA). Final Thoughts: Strategic healthtech acquirers are funding new deals in a variety of ways, including: Cash on hand. Many strategic acquirers have significant cash reserves that they can use to fund acquisitions. This is often the most common way for strategic acquirers to fund deals, as it is the most straightforward and efficient. Debt financing. Strategic acquirers can also use debt financing to fund acquisitions. This involves borrowing money from a bank or other lender. Debt financing can be a more expensive way to fund deals, but it can also be more flexible, as it allows acquirers to borrow more money than they have on hand. Stock financing. Strategic acquirers can also use stock financing to fund acquisitions. This involves issuing new shares of stock to the target company's shareholders. Stock financing can be a more dilutive way to fund deals, but it can also be more attractive to target companies, as it gives them an ownership stake in the acquirer. Hybrid financing. Strategic acquirers can also use a combination of cash, debt, and stock financing to fund acquisitions. This is often the case when acquirers are looking to maximize their flexibility and minimize their costs. Venture capital. Venture capital firms invest in early-stage companies with the potential for high growth. This can be a good way for strategic acquirers to acquire companies with cutting-edge technologies or innovative business models. Private equity. Private equity firms invest in established companies that they believe can be improved through restructuring or other changes. This can be a good way for strategic acquirers to acquire companies with strong market positions or valuable assets. The specific way that a strategic healthtech acquirer funds a new deal will depend on a variety of factors, including the size of the deal, the acquirer's financial situation, and the target company's preferences. In recent years, there has been a growing trend of strategic healthtech acquirers using alternative financing methods, such as venture capital and private equity. This is due to the increasing cost of acquisitions and the difficulty of raising debt financing in a challenging economic environment. Overall, the way that strategic healthtech acquirers fund new deals is becoming more diverse and creative. This is due to the increasing complexity and competition of the healthtech industry. Strategic acquirers are looking for ways to fund deals that are both efficient and flexible, and they are increasingly willing to explore alternative financing methods. Engage with the HealthTech Community HealthTech M&A Newsletter from Nelson Advisors - Market Insights & Analysis for Founders & Investors. Subscribe today! https://lnkd.in/e5hTp_xb HealthTech M&A Advisory by Founders for Founders, Owners & Investors. Buy Side, Sell Side, Growth and Strategy mandates - Email lloyd@nelsonadvisors.co.uk HealthTech Thought Leadership from Nelson Advisors - Industry Insights & Analysis for Founders, Owners & Investors. Visit https://www.healthcare.digital

10 Years ago I was fortunate enough to be interviewed by The Economist discussing Zesty my new Digital Health startup, HealthTech and the coming digital transformation in healthcare. Source: https://www.economist.com/schumpeter/2013/08/14/e-ppointments Will patients will shop around online for a doctor like tourists do for a hotel on TripAdvisor? RIGHT after 8.30am is a busy time for the ill in Britain. Many medical surgeries do not allow patients to pre-book appointments with their doctors: people must call up in the morning to book an appointment later in the afternoon. Come opening time, the phone lines are jammed with hacking, spluttering sick people trying to beg an audience with their doctor. Being able to book appointments online and outside of office hours not only makes life easier for patients, but gives them more choice. Zesty, a start-up based in London, has signed up 200 dental practices across ten London boroughs since launching at the end of April. Further healthcare sectors, such as surgeries, physiotherapists and osteopaths, will be implemented into its online booking system later this month. Co-founder Lloyd Price is banking on medicine being the next sector to take advantage of e-commerce. He wagers an online interface to make appointments and to compare doctors and dentists against each other, similar to the hotel-booking and rating model perfected by TripAdvisor and Expedia, will replace the engaged-tone at surgeries up and down the land. There is certainly money to be made from the ill: though Britain provides free healthcare for all via the National Health Service (NHS), a fifth of the population supplements state care with paid private health programmes. Zesty charges dentists £80 ($123) per month to be listed on its site. Yet the notion of a simple online or app-based booking system is an idealistic one, and not without its flaws. Health services are more frequently used by older people: two-thirds of those admitted to hospital in Britain are over 65. They are unlikely to be as comfortable with booking appointments online as the young. Still, claims Mr Price, 60% of Zesty’s bookings are made by those over 45 years old. He can also look across the Atlantic for evidence that people will book appointments via start-up apps. ZocDoc, an American health tech company, allows potential patients to search for a physician by location, speciality or the type of insurance they accept. Patients can schedule an appointment on their smartphones. Investors including Jeff Bezos, founder of Amazon, have put $95m into ZocDoc since its launch in 2007. The company claims 2.5m users a month across 1,800 American cities. Doctors pay $300 per month to be listed on the site. At home Zesty is up against a big established rival. Patient Access says a quarter of Britain’s medical practices use its system, which allows users to book appointments, order repeat prescriptions, notify practices of a change of address or send messages to their general practitioners (GPs). Patient Access requires users to have registered with a practice, rather than searching from nearby doctors signed up with the service. If toothache or a sharp pain strikes during the night, Zesty bets its users will be able to sleep better knowing they have an appointment pre-booked without gambling on the morning phone-line lottery. But whether patients will, in practice, shop around for a doctor like tourists do for a hotel on TripAdvisor is yet to be seen. Source: https://www.economist.com/schumpeter/2013/08/14/e-ppointments Engage with the HealthTech Community HealthTech M&A Newsletter from Nelson Advisors - Market Insights & Analysis for Founders & Investors. Subscribe today! https://lnkd.in/e5hTp_xb HealthTech M&A Advisory by Founders for Founders, Owners & Investors. Buy Side, Sell Side, Growth and Strategy mandates - Email lloyd@nelsonadvisors.co.uk HealthTech Thought Leadership from Nelson Advisors - Industry Insights & Analysis for Founders, Owners & Investors. Visit https://www.healthcare.digital

Exec Summary: The European HealthTech M&A market is expected to remain active in 2023, albeit with some slowdown from the record-breaking levels seen in 2022. The key trends that are expected to shape the market in 2023 include: Increased focus on digital health: Healthcare companies are increasingly looking to acquire digital health businesses in order to improve their offerings and stay ahead of the competition. This is being driven by the increasing adoption of digital health technologies by patients and healthcare providers, as well as the growing need for healthcare organizations to improve efficiency and reduce costs. Growth of the life sciences sector: The life sciences sector is expected to continue to grow in 2023, driven by the development of new drugs and therapies, as well as the increasing demand for personalized medicine. This growth is expected to create opportunities for M&A activity, as pharmaceutical companies look to acquire smaller, innovative biotech companies. Consolidation of the healthcare industry: The healthcare industry is consolidating, as larger companies acquire smaller ones in order to gain market share and scale. This trend is expected to continue in 2023, particularly in the areas of primary care, diagnostics, and hospital services. Increased regulatory scrutiny: The regulatory environment for M&A in the healthcare sector is becoming more complex, as governments around the world seek to protect patients and ensure the safety and efficacy of new products and services. This is expected to lead to longer and more complex approval processes for M&A deals in the healthcare sector. The following are some of the specific subsectors of the European HealthTech M&A market that are expected to be active in 2023: Digital health: This includes companies that develop and provide software, hardware, and services for the healthcare industry. Some of the key subsectors within digital health include: Telehealth: This includes companies that provide remote patient monitoring, virtual doctor visits, and other services. Artificial intelligence (AI): This includes companies that develop AI-powered solutions for healthcare, such as diagnostics, drug discovery, and clinical decision support. Wearable devices: This includes companies that develop and sell wearable devices that track health data, such as fitness trackers and smartwatches. Life sciences: This includes companies that develop and commercialize drugs, biologics, and medical devices. Some of the key subsectors within life sciences include: Oncology: This includes companies that develop and commercialize cancer drugs and therapies. Cardiovascular: This includes companies that develop and commercialize drugs and therapies for heart disease and stroke. Immunology: This includes companies that develop and commercialize drugs and therapies for autoimmune diseases. Diagnostics: This includes companies that develop and commercialize diagnostic tests and devices. Some of the key subsectors within diagnostics include: Molecular diagnostics: This includes companies that develop and commercialize tests that analyze DNA and RNA. Imaging: This includes companies that develop and commercialize medical imaging devices, such as MRI machines and CT scanners. Average multiples for HealthTech M&A deals The overall outlook for the European HealthTech M&A market in 2023 is positive, with continued growth expected in the key subsectors mentioned above. However, the market is likely to face some challenges, such as rising interest rates and increased regulatory scrutiny. The average enterprise value (EV) to sales multiple for HealthTech M&A deals in Europe is expected to be around 5x in 2023. This is down from the levels seen in 2022, but it is still higher than the average EV to sales multiple for all industries. Engage with the HealthTech Community HealthTech M&A Newsletter from Nelson Advisors - Market Insights & Analysis for Founders & Investors. Subscribe today! https://lnkd.in/e5hTp_xb HealthTech M&A Advisory by Founders for Founders, Owners & Investors. Buy Side, Sell Side, Growth and Strategy mandates - Email lloyd@nelsonadvisors.co.uk HealthTech Thought Leadership from Nelson Advisors - Industry Insights & Analysis for Founders, Owners & Investors. Visit https://www.healthcare.digital Digital Health - European HealthTech M&A market 2023: The increased focus on digital health in the European HealthTech M&A market in 2023 is being driven by a number of factors, including: The growing adoption of digital health solutions by patients and providers. The increasing availability of data and analytics. The need for healthcare companies to improve their efficiency and effectiveness. The desire to stay ahead of the competition. Some of the specific areas of digital health that are expected to see the most M&A activity in 2023 include: Telehealth: This includes companies that provide remote patient care services, such as video conferencing and online chat. Wearables and sensors: This includes companies that develop and manufacture wearable devices, such as fitness trackers and smartwatches, and sensors that can be used to collect data on patients' health. EHRs and patient portals: This includes companies that develop and provide electronic health records (EHRs) and patient portals, which allow patients to access their health information online. AI and machine learning: This includes companies that develop and use artificial intelligence (AI) and machine learning to improve healthcare delivery. Drug discovery and development: This includes companies that use digital health technologies to develop new drugs and treatments. Life Sciences - European HealthTech M&A market 2023: The growth of the life sciences sector is another key trend that is expected to shape the European HealthTech M&A market in 2023. This growth is being driven by a number of factors, including: The aging population, which is leading to an increased demand for new treatments for age-related diseases. The increasing prevalence of chronic diseases, such as cancer and diabetes. The growing demand for personalized medicine, which is tailored to the individual patient's needs. The advances in technology, which are making it possible to develop new and more effective treatments. Some of the specific areas of the life sciences sector that are expected to see the most M&A activity in 2023 include: Drug discovery and development: This includes companies that are developing new drugs and treatments for diseases. Biotechnology: This includes companies that are developing new technologies for the production of biological products, such as vaccines and gene therapies. Medical devices: This includes companies that are developing new medical devices, such as implants and imaging equipment. Diagnostics: This includes companies that are developing new diagnostic tests and devices. Regenerative medicine: This includes companies that are developing new technologies for the repair or regeneration of damaged tissues and organs. Healthcare IT - European HealthTech M&A market 2023 The increased focus on Healthcare IT in the European HealthTech M&A market in 2023 is being driven by a number of factors, including: The need for healthcare organizations to improve their efficiency and effectiveness. The desire to stay ahead of the competition. The growing adoption of digital health solutions by patients and providers. The increasing availability of data and analytics. Some of the specific areas of Healthcare IT that are expected to see the most M&A activity in 2023 include: Electronic health records (EHRs): This includes companies that develop and provide EHR software and services. Patient portals: This includes companies that develop and provide patient portals, which allow patients to access their health information online. Remote patient monitoring (RPM): This includes companies that develop and provide RPM solutions, which allow healthcare providers to monitor patients remotely. Clinical decision support (CDS): This includes companies that develop and provide CDS solutions, which help healthcare providers make better decisions about patient care. Healthcare analytics: This includes companies that develop and provide healthcare analytics solutions, which help healthcare organizations make better use of data. Final Thoughts: The average enterprise value (EV) to sales multiple for HealthTech M&A deals in Europe is expected to be around 5x in 2023. This is down from the levels seen in 2022, but it is still higher than the average EV to sales multiple for all industries. The specific subsectors of the European HealthTech market that are expected to see the most M&A activity in 2023: Digital health: This includes companies that develop and provide software, hardware, and services for the healthcare industry. Life sciences: This includes companies that develop and manufacture drugs, vaccines, and other medical products. Medical devices: This includes companies that develop and manufacture medical devices, such as implants, imaging equipment, and surgical robots. Diagnostics: This includes companies that develop and manufacture diagnostic tests and devices. Healthcare IT: This includes companies that develop and provide software and services for the healthcare industry, such as electronic health records (EHRs) and patient portals. Engage with the HealthTech Community HealthTech M&A Newsletter from Nelson Advisors - Market Insights & Analysis for Founders & Investors. Subscribe today! https://lnkd.in/e5hTp_xb HealthTech M&A Advisory by Founders for Founders, Owners & Investors. Buy Side, Sell Side, Growth and Strategy mandates - Email lloyd@nelsonadvisors.co.uk HealthTech Thought Leadership from Nelson Advisors - Industry Insights & Analysis for Founders, Owners & Investors. Visit https://www.healthcare.digital